<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancers (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Cancers (Basel)</journal-id><journal-id journal-id-type="publisher-id">cancers</journal-id><journal-title-group><journal-title>Cancers</journal-title></journal-title-group><issn pub-type="epub">2072-6694</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC10000102</article-id><article-id pub-id-type="doi">10.3390/cancers15051381</article-id><article-id pub-id-type="publisher-id">cancers-15-01381</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0753-0859</contrib-id><name><surname>Derry-Vick</surname><given-names>Heather M.</given-names></name><xref rid="af1-cancers-15-01381" ref-type="aff">1</xref><xref rid="af2-cancers-15-01381" ref-type="aff">2</xref><xref rid="c1-cancers-15-01381" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Heathcote</surname><given-names>Lauren C.</given-names></name><xref rid="af3-cancers-15-01381" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1489-6536</contrib-id><name><surname>Glesby</surname><given-names>Nina</given-names></name><xref rid="af4-cancers-15-01381" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Stribling</surname><given-names>Judy</given-names></name><xref rid="af5-cancers-15-01381" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Luebke</surname><given-names>Matthew</given-names></name><xref rid="af2-cancers-15-01381" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Epstein</surname><given-names>Andrew S.</given-names></name><xref rid="af6-cancers-15-01381" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7075-4268</contrib-id><name><surname>Prigerson</surname><given-names>Holly G.</given-names></name><xref rid="af5-cancers-15-01381" ref-type="aff">5</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Wong</surname><given-names>David</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Abdelrahim</surname><given-names>Maen</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-cancers-15-01381"><label>1</label>Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA</aff><aff id="af2-cancers-15-01381"><label>2</label>Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA</aff><aff id="af3-cancers-15-01381"><label>3</label>Health Psychology Section, Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King&#x02019;s College London, London SE1 9RT, UK</aff><aff id="af4-cancers-15-01381"><label>4</label>Smith College, Northampton, MA 01063, USA</aff><aff id="af5-cancers-15-01381"><label>5</label>Weill Cornell Medicine, New York, NY 10021, USA</aff><aff id="af6-cancers-15-01381"><label>6</label>Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA</aff><author-notes><corresp id="c1-cancers-15-01381"><label>*</label>Correspondence: <email>heather.derryvick@hmh-cdi.org</email></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>2</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2023</year></pub-date><volume>15</volume><issue>5</issue><elocation-id>1381</elocation-id><history><date date-type="received"><day>05</day><month>1</month><year>2023</year></date><date date-type="rev-recd"><day>14</day><month>2</month><year>2023</year></date><date date-type="accepted"><day>17</day><month>2</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><sec><title>Simple Summary</title><p>&#x0201c;Scanxiety&#x0201d;, or the distress and/or anxiety occurring before, during, and after cancer-related imaging/scans, is an upsetting experience during and following cancer. To better understand the nature of scanxiety, related research gaps and practices, and possible ways to help manage it, we conducted a review of the literature using a structured search process. We identified and synthesized findings from 36 articles on scanxiety among adults diagnosed with current or prior cancer. We found that scanxiety occurs across the cancer continuum. The articles also indicated that there are various components of the scan experience that prompt anxiety, such as those related to scan procedures and those related to the implications of important test results. The waiting period between the scan procedure and receipt of the results was described as particularly stressful. Our review also summarizes measures and methods used in scanxiety research. We discuss how the findings of this review may be used to inform future research directions and to generate approaches for helping people to manage scanxiety.</p></sec><sec><title>Abstract</title><p><bold>Background</bold>: Scan-related anxiety (&#x0201c;scanxiety&#x0201d;) is distressing to people living with and beyond cancer. We conducted a scoping review to promote conceptual clarity, identify research practices and gaps, and guide intervention strategies for adults with a current or prior cancer diagnosis. <bold>Methods:</bold> Following a systematic search, we screened 6820 titles and abstracts, evaluated 152 full-text articles, and selected 36 articles. Definitions, study designs, measurement methods, correlates, and consequences of scanxiety were extracted and summarized. <bold>Results:</bold> The reviewed articles included individuals living with current cancer (n = 17) and those in the post-treatment phase (n = 19), across a breadth of cancer types and disease stages. In five articles, authors explicitly defined scanxiety. Multiple components of scanxiety were described, including those related to scan procedures (e.g., claustrophobia, physical discomfort) and scan results (e.g., implications for disease status and treatment), suggesting varied intervention approaches may be needed. Twenty-two articles used quantitative methods, nine used qualitative methods, and five used mixed methods. In 17 articles, symptom measures specifically referenced cancer scans; 24 included general measures without reference to scans. Scanxiety tended to be higher among those with lower education levels, less time since diagnosis, and greater baseline anxiety levels (three articles each). Although scanxiety often decreased immediately pre- to post-scan (six articles), participants reported the waiting period between scan and results to be particularly stressful (six articles). Consequences of scanxiety included poorer quality of life and somatic symptoms. Scanxiety promoted follow-up care for some patients yet hindered it for others. <bold>Conclusions:</bold> Scanxiety is multi-faceted, heightened during the pre-scan and scan-to-results waiting periods, and associated with clinically meaningful outcomes. We discuss how these findings can inform future research directions and intervention approaches.</p></sec></abstract><kwd-group><kwd>Scanxiety</kwd><kwd>cancer</kwd><kwd>imaging</kwd><kwd>scan</kwd><kwd>stress</kwd><kwd>anxiety</kwd></kwd-group><funding-group><award-group><funding-source>National Cancer Institute</funding-source><award-id>K99/R00 CA245488</award-id><award-id>R35 CA197730</award-id><award-id>P30 CA008748</award-id></award-group><funding-statement>Work on this scoping review was supported by the National Cancer Institute (K99/R00 CA245488; R35 CA197730; P30 CA008748). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-cancers-15-01381"><title>1. Introduction</title><p>&#x0201c;Scanxiety&#x0201d; (defined here as distress and/or anxiety occurring before, during, and after cancer-related imaging/scans [<xref rid="B1-cancers-15-01381" ref-type="bibr">1</xref>,<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>,<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>]) is widely recognized as upsetting in patient reports, popular press, and patient education materials [<xref rid="B1-cancers-15-01381" ref-type="bibr">1</xref>,<xref rid="B4-cancers-15-01381" ref-type="bibr">4</xref>,<xref rid="B5-cancers-15-01381" ref-type="bibr">5</xref>]. Given that scans yield highly personal and consequential results regarding disease status, treatment response, and recurrence, it is not surprising that awaiting these results can be anxiety-provoking for patients during and following cancer treatment. Indeed, stress and anxiety are often ranked as highly concerning for patients awaiting scan results [<xref rid="B6-cancers-15-01381" ref-type="bibr">6</xref>], and people living with cancer report that scanxiety is a notable and challenging part of their cancer experience [<xref rid="B7-cancers-15-01381" ref-type="bibr">7</xref>]. Accordingly, summarizing the emerging empirical research on scanxiety among people with cancer has the potential to advance the science of cancer survivorship, as well as to inform potential intervention approaches that may ease this difficult time period that arises repeatedly for cancer survivors.</p><p>In a prior scoping review, Bui and colleagues summarized the quantitative measurement methods, prevalence, and severity of scanxiety among those with and without cancer. They concluded that the literature lacked a consistent definition of scanxiety [<xref rid="B8-cancers-15-01381" ref-type="bibr">8</xref>]. There remains a need to clarify scanxiety&#x02019;s definition and components in order to inform measurement and intervention strategies. A useful approach for doing so is to integrate qualitative research on patients&#x02019; experiences. Furthermore, because those with cancer repeatedly experience uncertainty about disease status while undergoing follow-up scans to establish stage and treatment plans, evaluate progression and treatment response, and detect recurrence, they may have unique scanxiety experiences and needs compared to those without cancer who undergo screening procedures. Accordingly, there is a need to advance the conceptualization of scanxiety by including qualitative findings, to review scanxiety literature specifically in those diagnosed with cancer, and to inform broad research directions in this area.</p><p>In this systematic scoping review, we synthesized findings from empirical articles on scanxiety among adults living with (e.g., those with current disease or in active treatment) and beyond (e.g., those deemed cured, post-treatment, or in remission) cancer. The objectives of this review were to describe the definitions, measurement methods, symptom levels, and correlates of scanxiety, and to identify research gaps and promising strategies for intervention. To achieve these objectives, we conducted a scoping review with a systematic search strategy. Given the current lack of conceptual clarity and to take an inclusive approach, we considered a range of psychological symptoms around a scan (including distress, stress, and anxiety) to reflect scanxiety. In this review, we describe the multi-faceted nature of scanxiety, outline measures that specifically focus on anxiety with respect to scans versus those that measure more general anxiety, and summarize research conducted to date regarding scanxiety&#x02019;s correlates and consequences. We then discuss how this information can inform future research directions and opportunities for intervention strategies during this stressful yet under-addressed period in clinical care.</p></sec><sec sec-type="methods" id="sec2-cancers-15-01381"><title>2. Methods</title><p>Because our goals were to examine and clarify definitions of scanxiety and its components, the methods used to study it, and current knowledge gaps, we selected a scoping review method (vs. a systematic review method to address a more specific research question, [<xref rid="B9-cancers-15-01381" ref-type="bibr">9</xref>]). We used a previously-established scoping review methodology to guide our study methods and applied the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Scoping Reviews [<xref rid="B9-cancers-15-01381" ref-type="bibr">9</xref>,<xref rid="B10-cancers-15-01381" ref-type="bibr">10</xref>,<xref rid="B11-cancers-15-01381" ref-type="bibr">11</xref>]. A protocol describing the objectives, inclusion criteria, and methods was posted on Open Science Framework (osf.io/wm79v) in March 2021 [<xref rid="B12-cancers-15-01381" ref-type="bibr">12</xref>]. As described below, the approach was updated to include an interim search and updated data extraction procedures, due to the time elapsed after the updated search as well as institution changes among multiple co-authors. For similar reasons, the data extraction phase included one rater (rather than two as initially planned) to chart the data for each included article.</p><p>References were compiled through a systematic search conducted by a librarian with expertise in clinical medicine (J.S.). Based upon initial search terms generated by the corresponding author (H.M.D.V.: cancer; scan; imaging; CT; MRI; recurrence; anxiety; distress; stress; scanxiety), the librarian constructed an extensive search strategy with expanded terms. The three main search clusters were cancer survivors, check-ups involving imaging, and patient anxiety. Medical Subject Headings, Emtree, PsycINFO and Cochrane terms were combined within each cluster using &#x02018;OR&#x02019;; these clusters were then combined using &#x02018;AND&#x02019;. The search strategy is available in the <xref rid="app1-cancers-15-01381" ref-type="app">Supplementary Materials</xref>.</p><p>The databases searched were MEDLINE, Embase, PsycINFO, CINAHL, Cochrane and Web of Science. The initial search was conducted in July 2020 for articles published in English between 1 January 1980 and 31 July 2020, and an updated search was conducted in March 2021. In order to include interim articles, the first author also conducted a limited search in PubMed up to July 2022. Reference management, abstract/title and full-text screening decisions, and data extraction utilized the Covidence reference management system.</p><p>Prior to initial article screening, references were downloaded into Endnote and then transferred to the Covidence review management system, which was used to identify and remove duplicates. The remaining titles and abstracts were then screened for inclusion using initial eligibility criteria that were clarified through consensus meetings. Titles and abstracts were indicated for inclusion if they reported data from adults undergoing cancer-related imaging tests, who also had a measure of psychological symptoms or recalled symptoms experienced around the time of the scan. Using these criteria, abstracts and titles were screened independently by two team members (N.G., M.L., and/or H.M.D.V.) for possible inclusion. Disagreements for initial screening were resolved via tiebreaker vote from the third member.</p><p>For records that met the initial criteria, full texts were reviewed by two study authors (H.M.D.V. and L.C.H.) and evaluated for final inclusion. The initial eligibility criteria above were refined to guide the full-text review phase and revised iteratively via consensus discussions (<xref rid="cancers-15-01381-t001" ref-type="table">Table 1</xref>). Inclusion and exclusion decisions (along with exclusion reasons) for the full-text review phase were recorded using Covidence. Disagreements were resolved via consensus discussion between the two raters.</p><p>The first author developed a data abstraction template and utilized this tool to extract and chart the data from the included articles. The following information was extracted by a single rater from the included articles as available: study design and methodology; demographic and cancer-related characteristics of participants; study definition of scanxiety; methods, instrument, and timing of scanxiety assessment; levels of scanxiety symptoms from quantitative measures; predictors and correlates of scanxiety; characteristics of the scan; and descriptions and effects of interventions. For qualitative articles, we also extracted themes and descriptions of scanxiety. Based on the goals of this scoping review, critical appraisal tools were not used.</p><p>To synthesize results, we grouped articles into those that used quantitative, qualitative, and mixed methods. To gain insight into research gaps, we summarized measurement characteristics (e.g., whether the study used a previously-established or newly-created measure; whether the assessment referenced scanxiety or scans specifically or instead included general measures of anxiety/stress) and the timing of assessments with respect to the scan. In addition, we grouped articles according to period in the cancer continuum (during vs. post-treatment) and summarized the cancer types and stages of the study samples&#x02019; participants. To gain insight on promising intervention strategies, we reviewed articles&#x02019; results for correlates of scanxiety to identify modifiable characteristics, and applied expertise in clinical psychology to suggest how these patterns could inform intervention development.</p></sec><sec sec-type="results" id="sec3-cancers-15-01381"><title>3. Results</title><p>The systematic search of multiple databases returned 10,319 references, as summarized by the PRISMA flow diagram in <xref rid="cancers-15-01381-f001" ref-type="fig">Figure 1</xref>. After removing duplicates, 6,820 titles and abstracts were screened. Of these, 152 full-text articles were evaluated for inclusion, including eight identified in the updated search. At the full-text review stage, articles were most frequently excluded due to a focus on individuals without current or prior cancer (such as those undergoing initial cancer screening) or due to not incorporating scans into the study design, data collection, or results. Ultimately, 36 full-text articles were included in the review.</p><sec id="sec3dot1-cancers-15-01381"><title>3.1. Study Types and Designs</title><p>There were 22 quantitative articles, summarizing 8 cross-sectional [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>,<xref rid="B16-cancers-15-01381" ref-type="bibr">16</xref>,<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>,<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>,<xref rid="B19-cancers-15-01381" ref-type="bibr">19</xref>,<xref rid="B20-cancers-15-01381" ref-type="bibr">20</xref>], 12 longitudinal [<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>,<xref rid="B16-cancers-15-01381" ref-type="bibr">16</xref>,<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>,<xref rid="B22-cancers-15-01381" ref-type="bibr">22</xref>,<xref rid="B23-cancers-15-01381" ref-type="bibr">23</xref>,<xref rid="B24-cancers-15-01381" ref-type="bibr">24</xref>,<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>,<xref rid="B26-cancers-15-01381" ref-type="bibr">26</xref>,<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>,<xref rid="B28-cancers-15-01381" ref-type="bibr">28</xref>], and 2 intervention trial study designs [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>]. There were 9 qualitative [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>,<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>,<xref rid="B26-cancers-15-01381" ref-type="bibr">26</xref>,<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>,<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>,<xref rid="B32-cancers-15-01381" ref-type="bibr">32</xref>,<xref rid="B33-cancers-15-01381" ref-type="bibr">33</xref>,<xref rid="B34-cancers-15-01381" ref-type="bibr">34</xref>,<xref rid="B35-cancers-15-01381" ref-type="bibr">35</xref>] and 5 mixed methods articles [<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>,<xref rid="B22-cancers-15-01381" ref-type="bibr">22</xref>,<xref rid="B28-cancers-15-01381" ref-type="bibr">28</xref>,<xref rid="B36-cancers-15-01381" ref-type="bibr">36</xref>,<xref rid="B37-cancers-15-01381" ref-type="bibr">37</xref>].</p></sec><sec id="sec3dot2-cancers-15-01381"><title>3.2. Definitions and Elements of &#x0201c;Scanxiety&#x0201d;</title><p>In five articles, authors explicitly defined scanxiety (<xref rid="cancers-15-01381-t002" ref-type="table">Table 2</xref>; [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>,<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>]). Several articles credited Bruce Feiler for first using and describing the term in his 2011 Time magazine article, who wrote that &#x0201c;scans are like revolving doors, emotional roulette wheels &#x02026;&#x0201d; and &#x0201c;[scans] engender &#x02018;scanxiety&#x02019; as they approach&#x0201d; [<xref rid="B1-cancers-15-01381" ref-type="bibr">1</xref>]. A common component of these definitions included a time course, suggesting that distress or anxiety can occur before, during, and after imaging procedures. One article explicitly emphasized that scanxiety is &#x0201c;normal&#x0201d; [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]. Among articles that did not define scanxiety, several did include a definition of a closely-related concept (e.g., fear of recurrence), or referenced that aspects of the scan experience can be stressful (e.g., &#x0201c;anxieties can be heightened around the time of a scan&#x02026;&#x0201d; [<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>]).</p><p>Several articles&#x02019; narratives described specific elements of the scan experience that may be anxiety-provoking for patients. Most commonly, articles noted the uncertainty and fear associated with what the results would show, and the implications of scan results for their disease status and treatment [<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>,<xref rid="B20-cancers-15-01381" ref-type="bibr">20</xref>,<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>]. Authors also described anxiety-provoking aspects of the imaging procedures, such as specialized or unfamiliar technology/equipment [<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>], discomfort [<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>], and claustrophobia arising from being in an enclosed space [<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>]. Concerns about exposure to radiation from the procedures were also noted [<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>]. Given the variety of concerns described, there are likely individual differences in what part of the scan experience is considered most stressful. These components suggest that scanxiety is multi-faceted, and people with cancer may have multiple and differing concerns relating to scans (<xref rid="cancers-15-01381-f002" ref-type="fig">Figure 2</xref>).</p><p>Quantitative results in several articles provided further detail on aspects of scanxiety. In a quantitative study of patients undergoing low dose PET/CT with 18-F-fluor-2-deoxi-D-glucose (<sup>18</sup>F-FDG), patients rated pre-selected reasons for their scanxiety [<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>]. Before a scan, 79% rated that they were most anxious about the results; others reported that they were most anxious about the scan procedure (12%), their illness (3%), or other areas (6%). This pattern did not change much afterwards in the post-scan assessment, with 87% reporting being most anxious about the scan results [<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>]. Other articles focused on the scan procedures (per the specific study goals), but did not appear to ask explicitly about anxiety related to the scan results. These articles illustrate additional concerns that patients may have around scans. For example, researchers focused on which experiences during MRI and PET/CT procedures were most stressful to esophageal cancer patients [<xref rid="B39-cancers-15-01381" ref-type="bibr">39</xref>]. Following a series of scans, participants reported that body position in the scanner (52%) and waiting time before scanning (19%) were most stressful during PET/CT. The noise of the scanner (26%), scan time (22%) and body position (22%) were noted as stressful during the MRI. Comparing the ratings for MRI versus PET/CT procedures showed that anxiety did not differ between them [<xref rid="B39-cancers-15-01381" ref-type="bibr">39</xref>]. In another quantitative study of cancer survivors in the United States who participated in the Health Information National Trends Survey (HINTS), 73% of respondents reported at least some worry about the effects of radiation from surveillance scans (i.e., medical imaging radiation; MIR), and 16% reported &#x0201c;a lot&#x0201d; of worry [<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>].</p><p>Qualitative findings also indicated a range of components of the scan experience that were stressful. For example, in focus groups, post-treatment breast cancer survivors described that undergoing scans reminded them of their initial diagnosis and promoted fears of recurrence [<xref rid="B32-cancers-15-01381" ref-type="bibr">32</xref>,<xref rid="B40-cancers-15-01381" ref-type="bibr">40</xref>]. Similarly, individual interviews with survivors of several cancer types suggested that scans served as a reminder of the &#x0201c;fragility of survivor status&#x0201d; and resulted in &#x0201c;iatrogenic uncertainty&#x0201d; [<xref rid="B33-cancers-15-01381" ref-type="bibr">33</xref>]. Claustrophobia [<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>], exposure to radiation [<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>], pain and discomfort associated with the procedures [<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>,<xref rid="B32-cancers-15-01381" ref-type="bibr">32</xref>], and receiving information from electronic reports [<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>] were also mentioned as sources of anxiety in qualitative interviews. Among people living with advanced cancer, results from open-ended questions and semi-structured interviews suggested that &#x0201c;most anxiety centered around the scan result and its implications&#x0201d; [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>] and that the procedures themselves were a less significant driver of anxiety [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>]. Taken together, these findings suggest that multiple aspects of scans may be anxiety-provoking for patients (<xref rid="cancers-15-01381-f002" ref-type="fig">Figure 2</xref>).</p></sec><sec id="sec3dot3-cancers-15-01381"><title>3.3. Populations Examined</title><p>Below, we summarize descriptive statistics of cancer-related characteristics from the articles&#x02019; samples. The number of articles summarized for these characteristics often exceeds the total number of included articles (n = 36) because some included individuals across multiple cancer types, stages, or other characteristics.</p><p>In 23 articles, the sample comprised individuals with a single cancer type [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B16-cancers-15-01381" ref-type="bibr">16</xref>,<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>,<xref rid="B23-cancers-15-01381" ref-type="bibr">23</xref>,<xref rid="B24-cancers-15-01381" ref-type="bibr">24</xref>,<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>,<xref rid="B26-cancers-15-01381" ref-type="bibr">26</xref>,<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>,<xref rid="B28-cancers-15-01381" ref-type="bibr">28</xref>,<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>,<xref rid="B32-cancers-15-01381" ref-type="bibr">32</xref>,<xref rid="B34-cancers-15-01381" ref-type="bibr">34</xref>,<xref rid="B36-cancers-15-01381" ref-type="bibr">36</xref>,<xref rid="B37-cancers-15-01381" ref-type="bibr">37</xref>,<xref rid="B39-cancers-15-01381" ref-type="bibr">39</xref>,<xref rid="B40-cancers-15-01381" ref-type="bibr">40</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>,<xref rid="B42-cancers-15-01381" ref-type="bibr">42</xref>,<xref rid="B43-cancers-15-01381" ref-type="bibr">43</xref>,<xref rid="B44-cancers-15-01381" ref-type="bibr">44</xref>,<xref rid="B45-cancers-15-01381" ref-type="bibr">45</xref>,<xref rid="B46-cancers-15-01381" ref-type="bibr">46</xref>]. In 13 articles, individuals with multiple cancer types were included in the sample [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>,<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>,<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>,<xref rid="B20-cancers-15-01381" ref-type="bibr">20</xref>,<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>,<xref rid="B22-cancers-15-01381" ref-type="bibr">22</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>,<xref rid="B33-cancers-15-01381" ref-type="bibr">33</xref>,<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>,<xref rid="B47-cancers-15-01381" ref-type="bibr">47</xref>,<xref rid="B48-cancers-15-01381" ref-type="bibr">48</xref>]. In two articles, individuals&#x02019; cancer type was not specified [<xref rid="B20-cancers-15-01381" ref-type="bibr">20</xref>,<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>]. Across articles, samples most commonly included people with breast (n = 18; [<xref rid="B8-cancers-15-01381" ref-type="bibr">8</xref>,<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B24-cancers-15-01381" ref-type="bibr">24</xref>,<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>,<xref rid="B26-cancers-15-01381" ref-type="bibr">26</xref>,<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>,<xref rid="B28-cancers-15-01381" ref-type="bibr">28</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B32-cancers-15-01381" ref-type="bibr">32</xref>,<xref rid="B33-cancers-15-01381" ref-type="bibr">33</xref>,<xref rid="B37-cancers-15-01381" ref-type="bibr">37</xref>,<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>,<xref rid="B40-cancers-15-01381" ref-type="bibr">40</xref>,<xref rid="B42-cancers-15-01381" ref-type="bibr">42</xref>,<xref rid="B44-cancers-15-01381" ref-type="bibr">44</xref>,<xref rid="B45-cancers-15-01381" ref-type="bibr">45</xref>,<xref rid="B48-cancers-15-01381" ref-type="bibr">48</xref>]), lung (n = 10; [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>,<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>,<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B33-cancers-15-01381" ref-type="bibr">33</xref>,<xref rid="B34-cancers-15-01381" ref-type="bibr">34</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>,<xref rid="B48-cancers-15-01381" ref-type="bibr">48</xref>]), or gastrointestinal (n = 9; [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>,<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>,<xref rid="B33-cancers-15-01381" ref-type="bibr">33</xref>,<xref rid="B36-cancers-15-01381" ref-type="bibr">36</xref>,<xref rid="B39-cancers-15-01381" ref-type="bibr">39</xref>,<xref rid="B46-cancers-15-01381" ref-type="bibr">46</xref>,<xref rid="B48-cancers-15-01381" ref-type="bibr">48</xref>]) cancer. Most articles included people with solid tumors, while fewer (n = 5; [<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>,<xref rid="B22-cancers-15-01381" ref-type="bibr">22</xref>,<xref rid="B33-cancers-15-01381" ref-type="bibr">33</xref>,<xref rid="B48-cancers-15-01381" ref-type="bibr">48</xref>]) included those with hematological malignancies (lymphoma or leukemia).</p><p>Seventeen articles included individuals living with cancer (i.e., those with current cancer, typically in active treatment [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>,<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>,<xref rid="B16-cancers-15-01381" ref-type="bibr">16</xref>,<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>,<xref rid="B23-cancers-15-01381" ref-type="bibr">23</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>,<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>,<xref rid="B34-cancers-15-01381" ref-type="bibr">34</xref>,<xref rid="B37-cancers-15-01381" ref-type="bibr">37</xref>,<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>,<xref rid="B39-cancers-15-01381" ref-type="bibr">39</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>,<xref rid="B46-cancers-15-01381" ref-type="bibr">46</xref>,<xref rid="B47-cancers-15-01381" ref-type="bibr">47</xref>,<xref rid="B48-cancers-15-01381" ref-type="bibr">48</xref>]), and 19 included individuals in the post-treatment period [<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>,<xref rid="B22-cancers-15-01381" ref-type="bibr">22</xref>,<xref rid="B24-cancers-15-01381" ref-type="bibr">24</xref>,<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>,<xref rid="B26-cancers-15-01381" ref-type="bibr">26</xref>,<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>,<xref rid="B28-cancers-15-01381" ref-type="bibr">28</xref>,<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>,<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>,<xref rid="B32-cancers-15-01381" ref-type="bibr">32</xref>,<xref rid="B33-cancers-15-01381" ref-type="bibr">33</xref>,<xref rid="B36-cancers-15-01381" ref-type="bibr">36</xref>,<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>,<xref rid="B40-cancers-15-01381" ref-type="bibr">40</xref>,<xref rid="B42-cancers-15-01381" ref-type="bibr">42</xref>,<xref rid="B43-cancers-15-01381" ref-type="bibr">43</xref>,<xref rid="B44-cancers-15-01381" ref-type="bibr">44</xref>,<xref rid="B45-cancers-15-01381" ref-type="bibr">45</xref>]. Three did not specify participants&#x02019; status along the cancer continuum [<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B20-cancers-15-01381" ref-type="bibr">20</xref>,<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>]. People with non-metastatic cancer were included in 22 articles [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>,<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B16-cancers-15-01381" ref-type="bibr">16</xref>,<xref rid="B23-cancers-15-01381" ref-type="bibr">23</xref>,<xref rid="B24-cancers-15-01381" ref-type="bibr">24</xref>,<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>,<xref rid="B26-cancers-15-01381" ref-type="bibr">26</xref>,<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>,<xref rid="B28-cancers-15-01381" ref-type="bibr">28</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>,<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>,<xref rid="B32-cancers-15-01381" ref-type="bibr">32</xref>,<xref rid="B36-cancers-15-01381" ref-type="bibr">36</xref>,<xref rid="B40-cancers-15-01381" ref-type="bibr">40</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>,<xref rid="B42-cancers-15-01381" ref-type="bibr">42</xref>,<xref rid="B43-cancers-15-01381" ref-type="bibr">43</xref>,<xref rid="B44-cancers-15-01381" ref-type="bibr">44</xref>,<xref rid="B46-cancers-15-01381" ref-type="bibr">46</xref>,<xref rid="B47-cancers-15-01381" ref-type="bibr">47</xref>], and those with metastatic cancer were included in 11 articles [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>,<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>,<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>,<xref rid="B34-cancers-15-01381" ref-type="bibr">34</xref>,<xref rid="B37-cancers-15-01381" ref-type="bibr">37</xref>,<xref rid="B42-cancers-15-01381" ref-type="bibr">42</xref>,<xref rid="B46-cancers-15-01381" ref-type="bibr">46</xref>,<xref rid="B47-cancers-15-01381" ref-type="bibr">47</xref>]. Specifically, 9 [<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B24-cancers-15-01381" ref-type="bibr">24</xref>,<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>,<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>,<xref rid="B28-cancers-15-01381" ref-type="bibr">28</xref>,<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>,<xref rid="B32-cancers-15-01381" ref-type="bibr">32</xref>,<xref rid="B40-cancers-15-01381" ref-type="bibr">40</xref>,<xref rid="B42-cancers-15-01381" ref-type="bibr">42</xref>], 14 [<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B16-cancers-15-01381" ref-type="bibr">16</xref>,<xref rid="B24-cancers-15-01381" ref-type="bibr">24</xref>,<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>,<xref rid="B26-cancers-15-01381" ref-type="bibr">26</xref>,<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>,<xref rid="B28-cancers-15-01381" ref-type="bibr">28</xref>,<xref rid="B32-cancers-15-01381" ref-type="bibr">32</xref>,<xref rid="B36-cancers-15-01381" ref-type="bibr">36</xref>,<xref rid="B40-cancers-15-01381" ref-type="bibr">40</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>,<xref rid="B42-cancers-15-01381" ref-type="bibr">42</xref>,<xref rid="B43-cancers-15-01381" ref-type="bibr">43</xref>,<xref rid="B46-cancers-15-01381" ref-type="bibr">46</xref>], 12 [<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B24-cancers-15-01381" ref-type="bibr">24</xref>,<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>,<xref rid="B26-cancers-15-01381" ref-type="bibr">26</xref>,<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>,<xref rid="B28-cancers-15-01381" ref-type="bibr">28</xref>,<xref rid="B32-cancers-15-01381" ref-type="bibr">32</xref>,<xref rid="B36-cancers-15-01381" ref-type="bibr">36</xref>,<xref rid="B40-cancers-15-01381" ref-type="bibr">40</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>,<xref rid="B42-cancers-15-01381" ref-type="bibr">42</xref>,<xref rid="B46-cancers-15-01381" ref-type="bibr">46</xref>], 16 [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>,<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B24-cancers-15-01381" ref-type="bibr">24</xref>,<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>,<xref rid="B26-cancers-15-01381" ref-type="bibr">26</xref>,<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>,<xref rid="B28-cancers-15-01381" ref-type="bibr">28</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B32-cancers-15-01381" ref-type="bibr">32</xref>,<xref rid="B36-cancers-15-01381" ref-type="bibr">36</xref>,<xref rid="B40-cancers-15-01381" ref-type="bibr">40</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>,<xref rid="B42-cancers-15-01381" ref-type="bibr">42</xref>,<xref rid="B46-cancers-15-01381" ref-type="bibr">46</xref>,<xref rid="B47-cancers-15-01381" ref-type="bibr">47</xref>], and 11 [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>,<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>,<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>,<xref rid="B34-cancers-15-01381" ref-type="bibr">34</xref>,<xref rid="B37-cancers-15-01381" ref-type="bibr">37</xref>,<xref rid="B42-cancers-15-01381" ref-type="bibr">42</xref>,<xref rid="B46-cancers-15-01381" ref-type="bibr">46</xref>,<xref rid="B47-cancers-15-01381" ref-type="bibr">47</xref>] articles included people with Stage 0, I, II, III, and IV disease, respectively. Thirteen articles did not specify the stage of participants&#x02019; cancer [<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>,<xref rid="B20-cancers-15-01381" ref-type="bibr">20</xref>,<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>,<xref rid="B22-cancers-15-01381" ref-type="bibr">22</xref>,<xref rid="B23-cancers-15-01381" ref-type="bibr">23</xref>,<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>,<xref rid="B33-cancers-15-01381" ref-type="bibr">33</xref>,<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>,<xref rid="B39-cancers-15-01381" ref-type="bibr">39</xref>,<xref rid="B44-cancers-15-01381" ref-type="bibr">44</xref>,<xref rid="B45-cancers-15-01381" ref-type="bibr">45</xref>,<xref rid="B48-cancers-15-01381" ref-type="bibr">48</xref>].</p><p>The reasons that participants were undergoing scans varied. Often, people who were undergoing scans for different reasons were included in the same studies. The most commonly listed purposes of scans were routine post-treatment monitoring to detect disease recurrence (n = 21; [<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>,<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>,<xref rid="B22-cancers-15-01381" ref-type="bibr">22</xref>,<xref rid="B24-cancers-15-01381" ref-type="bibr">24</xref>,<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>,<xref rid="B26-cancers-15-01381" ref-type="bibr">26</xref>,<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>,<xref rid="B28-cancers-15-01381" ref-type="bibr">28</xref>,<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>,<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>,<xref rid="B32-cancers-15-01381" ref-type="bibr">32</xref>,<xref rid="B33-cancers-15-01381" ref-type="bibr">33</xref>,<xref rid="B36-cancers-15-01381" ref-type="bibr">36</xref>,<xref rid="B40-cancers-15-01381" ref-type="bibr">40</xref>,<xref rid="B42-cancers-15-01381" ref-type="bibr">42</xref>,<xref rid="B43-cancers-15-01381" ref-type="bibr">43</xref>,<xref rid="B44-cancers-15-01381" ref-type="bibr">44</xref>,<xref rid="B45-cancers-15-01381" ref-type="bibr">45</xref>,<xref rid="B48-cancers-15-01381" ref-type="bibr">48</xref>]) and routine monitoring to detect disease progression or treatment response (n = 15; [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>,<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>,<xref rid="B16-cancers-15-01381" ref-type="bibr">16</xref>,<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>,<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>,<xref rid="B23-cancers-15-01381" ref-type="bibr">23</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>,<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>,<xref rid="B34-cancers-15-01381" ref-type="bibr">34</xref>,<xref rid="B37-cancers-15-01381" ref-type="bibr">37</xref>,<xref rid="B47-cancers-15-01381" ref-type="bibr">47</xref>,<xref rid="B48-cancers-15-01381" ref-type="bibr">48</xref>]). Other articles included participants undergoing scans for post-diagnosis staging or treatment planning (n = 6; [<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>,<xref rid="B39-cancers-15-01381" ref-type="bibr">39</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>,<xref rid="B46-cancers-15-01381" ref-type="bibr">46</xref>,<xref rid="B48-cancers-15-01381" ref-type="bibr">48</xref>]. Only one article included individuals who were undergoing investigative scans for new symptoms [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]. The scans&#x02019; purpose was not specified in two articles [<xref rid="B20-cancers-15-01381" ref-type="bibr">20</xref>,<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>]. Articles included a wide variety of scan types (<xref rid="cancers-15-01381-t003" ref-type="table">Table 3</xref>).</p></sec><sec id="sec3dot4-cancers-15-01381"><title>3.4. Measurement Methods</title><p>Measurement of psychological symptoms included diverse concepts, such as distress, anxiety, stress, fear of cancer recurrence, and emotional well-being. Some articles included assessments that were specifically worded with reference to a scan, while others included a measure of general symptoms without a specific focus. For the purpose of consistency and brevity, and to reflect that these concepts were measured around or associated with scan procedures, we refer to all of these psychological symptoms as &#x0201c;scanxiety&#x0201d; in this paper.</p><p>Quantitative measures were used in 27 articles, including the five mixed methods articles [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>,<xref rid="B16-cancers-15-01381" ref-type="bibr">16</xref>,<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>,<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>,<xref rid="B20-cancers-15-01381" ref-type="bibr">20</xref>,<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>,<xref rid="B22-cancers-15-01381" ref-type="bibr">22</xref>,<xref rid="B23-cancers-15-01381" ref-type="bibr">23</xref>,<xref rid="B24-cancers-15-01381" ref-type="bibr">24</xref>,<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>,<xref rid="B26-cancers-15-01381" ref-type="bibr">26</xref>,<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>,<xref rid="B28-cancers-15-01381" ref-type="bibr">28</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>,<xref rid="B37-cancers-15-01381" ref-type="bibr">37</xref>,<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>,<xref rid="B39-cancers-15-01381" ref-type="bibr">39</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>,<xref rid="B42-cancers-15-01381" ref-type="bibr">42</xref>,<xref rid="B43-cancers-15-01381" ref-type="bibr">43</xref>,<xref rid="B46-cancers-15-01381" ref-type="bibr">46</xref>,<xref rid="B47-cancers-15-01381" ref-type="bibr">47</xref>,<xref rid="B48-cancers-15-01381" ref-type="bibr">48</xref>]. Of these, 10 articles used more than one quantitative measure [<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>,<xref rid="B20-cancers-15-01381" ref-type="bibr">20</xref>,<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>,<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>,<xref rid="B42-cancers-15-01381" ref-type="bibr">42</xref>,<xref rid="B48-cancers-15-01381" ref-type="bibr">48</xref>]. The most frequently used quantitative assessment tools were single-item measures that were developed for the purpose of the given study. Such measures were used in eight articles [<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>,<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B39-cancers-15-01381" ref-type="bibr">39</xref>,<xref rid="B42-cancers-15-01381" ref-type="bibr">42</xref>,<xref rid="B46-cancers-15-01381" ref-type="bibr">46</xref>,<xref rid="B47-cancers-15-01381" ref-type="bibr">47</xref>,<xref rid="B48-cancers-15-01381" ref-type="bibr">48</xref>]. Across articles, there were 28 unique assessment tools; see <xref rid="cancers-15-01381-t004" ref-type="table">Table 4</xref>. There were 14 scan-specific measures (used across 17 articles) that were worded specifically with respect to scans, and 14 general measures (used across 24 studies) that assessed psychological symptoms without a specific reference to scans.</p><p>Among the articles that used quantitative measures, 20 provided information about the timing of survey administration with respect to the scan or scan results discussion [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>,<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>,<xref rid="B20-cancers-15-01381" ref-type="bibr">20</xref>,<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>,<xref rid="B23-cancers-15-01381" ref-type="bibr">23</xref>,<xref rid="B24-cancers-15-01381" ref-type="bibr">24</xref>,<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>,<xref rid="B26-cancers-15-01381" ref-type="bibr">26</xref>,<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>,<xref rid="B28-cancers-15-01381" ref-type="bibr">28</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>,<xref rid="B39-cancers-15-01381" ref-type="bibr">39</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>,<xref rid="B46-cancers-15-01381" ref-type="bibr">46</xref>,<xref rid="B47-cancers-15-01381" ref-type="bibr">47</xref>,<xref rid="B48-cancers-15-01381" ref-type="bibr">48</xref>]. In seven articles, the timing of survey administration was unspecified or was not timed with respect to the scan [<xref rid="B16-cancers-15-01381" ref-type="bibr">16</xref>,<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>,<xref rid="B22-cancers-15-01381" ref-type="bibr">22</xref>,<xref rid="B37-cancers-15-01381" ref-type="bibr">37</xref>,<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>,<xref rid="B42-cancers-15-01381" ref-type="bibr">42</xref>,<xref rid="B43-cancers-15-01381" ref-type="bibr">43</xref>]. In four articles, scanxiety was assessed only before a scan procedure or scan results discussion [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B20-cancers-15-01381" ref-type="bibr">20</xref>,<xref rid="B26-cancers-15-01381" ref-type="bibr">26</xref>,<xref rid="B47-cancers-15-01381" ref-type="bibr">47</xref>]. In five articles, scanxiety was assessed only after a scan or scan results discussion [<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>,<xref rid="B39-cancers-15-01381" ref-type="bibr">39</xref>,<xref rid="B46-cancers-15-01381" ref-type="bibr">46</xref>]. In 11 articles, scanxiety was assessed both before and after a scan procedure or scan results discussion [<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>,<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>,<xref rid="B23-cancers-15-01381" ref-type="bibr">23</xref>,<xref rid="B24-cancers-15-01381" ref-type="bibr">24</xref>,<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>,<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>,<xref rid="B28-cancers-15-01381" ref-type="bibr">28</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>,<xref rid="B48-cancers-15-01381" ref-type="bibr">48</xref>].</p><p>Fourteen articles used qualitative methods, including the five mixed methods articles that also incorporated quantitative measures above [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>,<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>,<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>,<xref rid="B32-cancers-15-01381" ref-type="bibr">32</xref>,<xref rid="B33-cancers-15-01381" ref-type="bibr">33</xref>,<xref rid="B34-cancers-15-01381" ref-type="bibr">34</xref>,<xref rid="B36-cancers-15-01381" ref-type="bibr">36</xref>,<xref rid="B37-cancers-15-01381" ref-type="bibr">37</xref>,<xref rid="B40-cancers-15-01381" ref-type="bibr">40</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>,<xref rid="B44-cancers-15-01381" ref-type="bibr">44</xref>,<xref rid="B45-cancers-15-01381" ref-type="bibr">45</xref>]. Of these, 13 articles used semi-structured interviews (n = 4 in focus groups [<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>,<xref rid="B32-cancers-15-01381" ref-type="bibr">32</xref>,<xref rid="B36-cancers-15-01381" ref-type="bibr">36</xref>,<xref rid="B40-cancers-15-01381" ref-type="bibr">40</xref>], n = 9 individually [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>,<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>,<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>,<xref rid="B33-cancers-15-01381" ref-type="bibr">33</xref>,<xref rid="B34-cancers-15-01381" ref-type="bibr">34</xref>,<xref rid="B37-cancers-15-01381" ref-type="bibr">37</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>,<xref rid="B44-cancers-15-01381" ref-type="bibr">44</xref>,<xref rid="B45-cancers-15-01381" ref-type="bibr">45</xref>]) and one used open text box responses [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]. In nine articles, the interview topic guides or open text questions explicitly asked about scanxiety or emotions with respect to scans [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>,<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>,<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>,<xref rid="B32-cancers-15-01381" ref-type="bibr">32</xref>,<xref rid="B34-cancers-15-01381" ref-type="bibr">34</xref>,<xref rid="B40-cancers-15-01381" ref-type="bibr">40</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>]. In the other five articles using qualitative methods, responses and themes regarding scanxiety emerged when asking other questions about cancer survivorship, follow-up care, and quality of life, and were thus reported in the results [<xref rid="B33-cancers-15-01381" ref-type="bibr">33</xref>,<xref rid="B36-cancers-15-01381" ref-type="bibr">36</xref>,<xref rid="B37-cancers-15-01381" ref-type="bibr">37</xref>,<xref rid="B44-cancers-15-01381" ref-type="bibr">44</xref>,<xref rid="B45-cancers-15-01381" ref-type="bibr">45</xref>].</p></sec><sec id="sec3dot5-cancers-15-01381"><title>3.5. Consequences of Scanxiety</title><p>Of the articles reviewed, eight quantitatively investigated [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>,<xref rid="B22-cancers-15-01381" ref-type="bibr">22</xref>,<xref rid="B24-cancers-15-01381" ref-type="bibr">24</xref>,<xref rid="B26-cancers-15-01381" ref-type="bibr">26</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>,<xref rid="B47-cancers-15-01381" ref-type="bibr">47</xref>] and five qualitatively summarized [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>,<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>,<xref rid="B33-cancers-15-01381" ref-type="bibr">33</xref>,<xref rid="B44-cancers-15-01381" ref-type="bibr">44</xref>,<xref rid="B45-cancers-15-01381" ref-type="bibr">45</xref>] the effects of scanxiety. These articles highlighted effects on quality of life, somatic symptoms, receipt of follow-up care, and other healthcare experiences.</p><sec id="sec3dot5dot1-cancers-15-01381"><title>3.5.1. Quality of Life</title><p>Several articles highlighted links between scanxiety and poorer quality of life. Patients with metastatic cancer who reported scanxiety had poorer quality of life on the EORTC-QLQ-30 than those who did not [<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>]. In another article, advanced lung cancer patients who experienced higher scanxiety reported poorer quality of life on the FACT-L than those with lower scanxiety [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>]. By examining the subscales of the FACT-L, the authors concluded that this relationship was primarily driven by an association between scanxiety and emotional well-being. Consistent with these findings, metastatic cancer patients&#x02019; anxiety as assessed before a scan results discussion was associated with poorer psychological well-being on the McGill quality of life questionnaire [<xref rid="B47-cancers-15-01381" ref-type="bibr">47</xref>].</p></sec><sec id="sec3dot5dot2-cancers-15-01381"><title>3.5.2. Somatic Symptoms</title><p>Findings from included articles suggested that scanxiety is linked to somatic symptoms. For example, advanced cancer patients reported that they experienced trouble sleeping (32%), feelings of dread (29%), poor concentration (26%), irritability (25%), and restlessness/agitation or tension (24%) due to scanxiety [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]. Other somatic symptoms including pain, low appetite, and racing heart, among others [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]. In a study of women undergoing mammograms following breast cancer treatment, participants with higher fear of cancer recurrence experienced poorer sleep both immediately before and one week after their mammograms compared to those with lower fear of cancer recurrence [<xref rid="B24-cancers-15-01381" ref-type="bibr">24</xref>]. Similarly, advanced cancer patients described difficulty sleeping, fatigue, irritability, poorer concentration, and lower motivation for daily activities in qualitative interviews [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>].</p></sec><sec id="sec3dot5dot3-cancers-15-01381"><title>3.5.3. Receipt and Experiences of Follow-Up Care</title><p>There were complex relationships between scanxiety and receipt of follow-up care, and the direction of the effects differed by article. For example, in a qualitative study of post-treatment lymphoma survivors, some reported that fear of recurrence motivated them to complete follow-up care, while others said it was a barrier [<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>]. These different patterns were also observed in quantitative studies. Among people with metastatic cancer, 16% reported that they had delayed follow-up care due to scanxiety [<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>]. A similar pattern was observed in post-treatment breast cancer survivors, such that those with higher levels of anticipatory anxiety were less likely to undergo mammography in the following year than those with lower levels of anticipatory anxiety [<xref rid="B26-cancers-15-01381" ref-type="bibr">26</xref>]. Specifically, compared to women without anticipatory anxiety, those with median levels of anticipatory anxiety were 32% less likely to undergo a mammogram in the next year. Women with higher anticipatory anxiety also reported more negative responses to pain during the mammogram, which partially explained the relationship between anxiety and mammogram adherence in a mediation model. Findings from a latent class analysis of adult survivors of childhood cancers indicated a different pattern [<xref rid="B22-cancers-15-01381" ref-type="bibr">22</xref>]. Those in the &#x0201c;worried&#x0201d; latent class were more likely to report completing mammography, as well as other aspects of follow-up care including ECG and bone densitometry, within the recommended time frame than those in other latent classes. Finally, in a study involving a series of three scans, baseline anxiety scores did not differ between those who went on to complete all of their scans in the series versus those who did not [<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>].</p><p>Qualitative findings added further context to these relationships. Following breast cancer treatment, some women noted that concern about recurrence was a motivator for completing follow-up surveillance care, while others reported that fear of recurrence was a barrier to follow-up care [<xref rid="B45-cancers-15-01381" ref-type="bibr">45</xref>]. Another article highlighted that mammography was perceived as reassuring, and thus &#x0201c;worth the discomfort it may cause&#x0201d;, suggesting that anxiety was not perceived as a barrier to completing follow-up mammograms [<xref rid="B44-cancers-15-01381" ref-type="bibr">44</xref>]. In survivors with various cancer diagnoses and cancer statuses, it was noted that follow-up tests (e.g., mammograms) were reassuring for some, while at least one participant noted that they did not experience this relief and considered discontinuing follow-up [<xref rid="B33-cancers-15-01381" ref-type="bibr">33</xref>].</p><p>The effects of scanxiety on other healthcare experiences were examined in two articles. Among advanced cancer patients, those with higher anxiety prior to a scan results discussion were less likely to report their recently-discussed scan results accurately (compared to their oncologists&#x02019; reports) than those with lower anxiety [<xref rid="B47-cancers-15-01381" ref-type="bibr">47</xref>]. In lung cancer patients, anxiety was not related to motion artifacts during the scan, which can affect the quality of the imaging for interpretation [<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>].</p></sec></sec><sec id="sec3dot6-cancers-15-01381"><title>3.6. Correlates of Scanxiety</title><p>Of the articles reviewed, 21 quantitatively evaluated factors that were associated with scanxiety [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>,<xref rid="B16-cancers-15-01381" ref-type="bibr">16</xref>,<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>,<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>,<xref rid="B20-cancers-15-01381" ref-type="bibr">20</xref>,<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>,<xref rid="B23-cancers-15-01381" ref-type="bibr">23</xref>,<xref rid="B24-cancers-15-01381" ref-type="bibr">24</xref>,<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>,<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>,<xref rid="B28-cancers-15-01381" ref-type="bibr">28</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>,<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>,<xref rid="B39-cancers-15-01381" ref-type="bibr">39</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>,<xref rid="B46-cancers-15-01381" ref-type="bibr">46</xref>,<xref rid="B48-cancers-15-01381" ref-type="bibr">48</xref>], and 12 described qualitative themes regarding such factors [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>,<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>,<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>,<xref rid="B32-cancers-15-01381" ref-type="bibr">32</xref>,<xref rid="B34-cancers-15-01381" ref-type="bibr">34</xref>,<xref rid="B37-cancers-15-01381" ref-type="bibr">37</xref>,<xref rid="B40-cancers-15-01381" ref-type="bibr">40</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>,<xref rid="B44-cancers-15-01381" ref-type="bibr">44</xref>,<xref rid="B45-cancers-15-01381" ref-type="bibr">45</xref>]. Findings are synthesized below, grouped by factors that reflect sociodemographic characteristics, cancer-related characteristics, scan-related factors, timing of assessment, clinic- and system-related factors, and psychological and behavioral factors.</p><sec id="sec3dot6dot1-cancers-15-01381"><title>3.6.1. Sociodemographic Characteristics</title><p>In two articles, women reported higher scanxiety or were more likely to endorse scanxiety compared to men [<xref rid="B20-cancers-15-01381" ref-type="bibr">20</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]. In Abreu and colleagues&#x02019; study, there were no gender differences in scanxiety prior to the scan procedure, but men reported higher scanxiety than women afterward [<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>]. Gender was not associated with scanxiety in four articles [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>,<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>], although there was a trend toward higher scanxiety in women in two of these articles [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>].</p><p>Age was not associated with scanxiety in most articles [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>,<xref rid="B23-cancers-15-01381" ref-type="bibr">23</xref>,<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>]. In a study of advanced cancer patients, younger participants were more likely to endorse experiencing scanxiety than older participants [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]. Similarly, in people undergoing active surveillance or primary intervention for kidney cancer, those who were younger had poorer mental health scores than those who were older [<xref rid="B16-cancers-15-01381" ref-type="bibr">16</xref>].</p><p>Few articles examined the relationship between scanxiety and race or ethnicity. In advanced lung cancer patients, there was no significant relationship between race or ethnicity and scanxiety [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>]. Among cancer survivors in the HINTS study, Black individuals and those who were foreign-born were more worried about exposure to medical imaging radiation than white and US-born individuals, respectively, in unadjusted analyses, but these relationships did not remain in adjusted models [<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>].</p><p>While education level was not associated with anxiety in three articles [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>], several articles suggested that scanxiety may be worse among those with lower education levels. In the HINTS study, cancer survivors with lower educational attainment reported more worry about medical imaging radiation than those with higher educational attainment in unadjusted analyses, but this relationship was weakened in adjusted models [<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>]. Similarly, people with lower education had higher scanxiety when undergoing imaging than those with higher education [<xref rid="B20-cancers-15-01381" ref-type="bibr">20</xref>]. In a study of advanced cancer patients, those with lower education levels were more likely to endorse scanxiety than those with higher education levels, but interestingly, health literacy was not associated with scanxiety [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]. In this study, participants who lived in more remote locations were also more likely to report experiencing scanxiety than those who lived in more urban locations [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>].</p><p>Other sociodemographic factors were not associated with anxiety or stress around the time of scans, including smoking status [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>], income [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>], and relationship/marital status [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]. Medical imaging radiation worry was not associated with health insurance status, but those with lower income levels were more likely to report medical imaging radiation worry than those with higher income levels [<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>].</p></sec><sec id="sec3dot6dot2-cancers-15-01381"><title>3.6.2. Cancer-Related Characteristics</title><p>Several articles included individuals with and without cancer and examined whether scanxiety varied with cancer history. Using daily data collection before and after mammograms, Porter and colleagues observed that breast cancer survivors had a slightly greater increase in daily stress from baseline to mammogram day compared to control women without a cancer history [<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>]. On the other hand, patients undergoing imaging tests for cancer had lower anxiety levels on the day of the exam than those who underwent imaging for other health conditions [<xref rid="B20-cancers-15-01381" ref-type="bibr">20</xref>]. In a three-week daily diary study, participants with cancer reported significantly higher fear of cancer recurrence across the study period and greater peak levels of fear of cancer recurrence on the day of their mammogram compared to their spouses [<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>]. Another study indicated a different pattern, in which 71% of patients and 81% of their caregivers reported scanxiety symptoms on a Greek version of the IES-R, though the score cutoff and statistical significance of this comparison was not reported in the conference abstract [<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>].</p><p>In two quantitative articles, time since diagnosis was not related to levels of scanxiety [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>]. Other articles suggested a complex relationship. Among advanced cancer patients, those who were diagnosed less than a year ago endorsed similar rates of experiencing scanxiety (vs. not experiencing scanxiety) compared to those who were diagnosed more than a year ago [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]. However, in the subset of participants who endorsed scanxiety, those who were diagnosed less than a year ago rated their peak anxiety as higher than those with a longer time since diagnosis [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]. In a cross-sectional study, patients with a recent diagnosis within six months or less had higher levels of scanxiety than those who had been living longer with cancer [<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>]. However, in the same study, participants also reported that scanxiety did not dissipate over time [<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>]. In the HINTS study, those who had completed treatment within the past 10 years reported higher worry about medical imaging radiation than those who had completed their treatment more than 10 years ago [<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>]. Qualitative findings similarly highlighted that scanxiety may decrease over time for some people with cancer, but not for others. For example, some patients with metastatic lung cancer reported that their anxiety diminished as their condition stabilized, while others reported that scanxiety is &#x0201c;always there&#x0201d; [<xref rid="B34-cancers-15-01381" ref-type="bibr">34</xref>]. Among veterans with bladder cancer, some noted that anxiety lessened over time with repeated procedures, and with meeting &#x0201c;experienced&#x0201d; patients who had been living with cancer for a longer period of time [<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>].</p><p>Few articles investigated differences in scanxiety based on cancer stage, cancer type, treatment type, or health status. Advanced lung cancer patients&#x02019; scanxiety did not vary according to their cancer histology, stage, or the presence of an actionable tumor mutation [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>]. Patients with progressive lung cancer did not experience significantly higher levels of scanxiety than those whose disease was stable or improving [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>]. On the other hand, cancer survivors with poorer self-rated health had higher levels of medical imaging radiation worry than those who rated their health better [<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>]. Larger proportions of those with breast and lung cancer reported higher medical imaging radiation worry compared to other cancer types, and those who received radiation treatment were more likely to report worry than those who did not [<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>]. Among those with advanced cancer, those with breast cancer were more likely to report experiencing scanxiety around a recent scan compared to those with other cancers [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]. Clinical trial participation was not associated with scanxiety [<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>].</p></sec><sec id="sec3dot6dot3-cancers-15-01381"><title>3.6.3. Scan-Related Characteristics</title><p>The number of prior scans or frequency of scans was not reported in most articles we reviewed. In two articles, anxiety level was not significantly different for those who were undergoing the <sup>18</sup>F-FDG PET/CT scan procedure for the first time compared to those who had completed it previously [<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>]. Similarly, among patients who were undergoing a series of multiple scan types, including MRI and CT, anxiety was not statistically different between the first and second MRIs [<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>]. Nevertheless, in qualitative interviews with advanced cancer patients, increasing familiarity with the procedures was noted to be linked to lower scanxiety [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>].</p><p>Findings were inconsistent for whether scanxiety varied by scan type. For example, among lung cancer patients undergoing CT and MRI scans, state anxiety scores did not differ significantly by scan type [<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>]. However, in the semi-structured interview component of this mixed methods study, participants described that MRI scans prompted more anxiety, claustrophobia, and discomfort than CT scans [<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>]. In Goense and colleagues&#x02019; study, participants underwent both MRI and PET/CT scans; they concluded that anxiety did not vary significantly by scan type [<xref rid="B39-cancers-15-01381" ref-type="bibr">39</xref>]. Follow-up regimen type was also not associated with differences in mental well-being between kidney cancer patients who received active surveillance including regular imaging (CT, MRI, and ultrasound) and those who received primary intervention [<xref rid="B16-cancers-15-01381" ref-type="bibr">16</xref>]. On the other hand, three studies found group differences in anxiety according to scan type, with anxiety being higher for MRI (vs. CT) [<xref rid="B20-cancers-15-01381" ref-type="bibr">20</xref>], for endoscopic ultrasonography (vs. cervical ultrasonography, CT, or PET) [<xref rid="B46-cancers-15-01381" ref-type="bibr">46</xref>], and for rigid (vs. flexible) cystoscopy [<xref rid="B23-cancers-15-01381" ref-type="bibr">23</xref>].</p><p>Several articles examined characteristics of the scan experience. For example, one study indicated that patients&#x02019; experiences during the scan (e.g., discomfort, difficulty) were associated with higher anxiety directly following the procedure [<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>]. Similarly, focus groups with breast cancer survivors suggested that pain and discomfort during mammogram procedures were a source of anxiety [<xref rid="B32-cancers-15-01381" ref-type="bibr">32</xref>]. The reason that the scan was being conducted was not related to anxiety [<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>]. Interestingly, a study of advanced cancer patients did not indicate a significant association between type of result received (stable or better vs. progressive) and retrospective anxiety reports [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]. Patients&#x02019; expectations about the nature of the results were also not associated with pre-scan distress levels [<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>]. Among advanced lung cancer patients attending an appointment, those who reviewed a recent scan during the visit did not have significantly higher scanxiety severity compared to those who did not review a scan at the visit [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>].</p></sec><sec id="sec3dot6dot4-cancers-15-01381"><title>3.6.4. Timing of Assessment</title><p>Articles with longitudinal designs examined the effect of time by comparing scanxiety at different points in the scan experience. In two articles, anxiety increased from baseline to pre-mammogram [<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>]. In six articles, anxiety decreased from pre- to post-scan procedure [<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>,<xref rid="B23-cancers-15-01381" ref-type="bibr">23</xref>,<xref rid="B24-cancers-15-01381" ref-type="bibr">24</xref>,<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>]. In one article, participants experienced higher anxiety following the scan compared with their pre-scan anxiety [<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>]. In at least two articles [<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B24-cancers-15-01381" ref-type="bibr">24</xref>], participants had received their results by the post-scan time point. However, the timing of results was not always clear with respect to the study assessments.</p></sec><sec id="sec3dot6dot5-cancers-15-01381"><title>3.6.5. Other Clinic or System-Level Factors</title><p>In qualitative articles, the waiting period between the scan procedure and receiving scan results was often described as the most distressing period [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>,<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>]. Participants described that anxiety was present until the results of the scan were known [<xref rid="B40-cancers-15-01381" ref-type="bibr">40</xref>,<xref rid="B44-cancers-15-01381" ref-type="bibr">44</xref>]. In separate articles of post-treatment breast cancer and lymphoma survivors, both research teams noted that the days between the scan and receiving results were particularly stressful and reminded participants of the time period of when they were first evaluated for and diagnosed with cancer [<xref rid="B40-cancers-15-01381" ref-type="bibr">40</xref>,<xref rid="B45-cancers-15-01381" ref-type="bibr">45</xref>]. Wait times may be shortened when receiving results electronically (e.g., via patient portals), which was perceived positively by some patients [<xref rid="B37-cancers-15-01381" ref-type="bibr">37</xref>]. Qualitative findings also suggested that other stressors arose with this option for some patients, such as the potential to feel worse after a &#x0201c;bad result&#x0201d; or to need reassurance from an oncologist [<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>,<xref rid="B37-cancers-15-01381" ref-type="bibr">37</xref>].</p><p>Although this waiting period was commonly noted as anxiety-provoking in qualitative articles, few quantitative articles examined this factor. Advanced cancer patients who waited more than two days for their scan results were more likely to retrospectively report experiencing scanxiety [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]. With respect to results delivery, advanced cancer patients who were notified about their results by their preferred provider had greater decreases in their distress following this discussion than those who received results from a provider that differed from their preference [<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>]. However, participants&#x02019; distress before imaging and after results was not associated with whether their preferences were met for the time frame or method for delivering results [<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>]. Among lymphoma patients, those who reported a worse patient&#x02013;doctor relationship had higher anxiety than those who reported a better relationship, although this assessment was not timed around scans specifically [<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>]. On the other hand, worry about medical imaging radiation was not associated with physician trust in a heterogeneous sample of cancer survivors [<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>].</p><p>In another article, advanced cancer patients rated clinic-level factors as helpful around the time of the scan or scan results [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>], although the statistical relationships between these factors and anxiety were not tested specifically. Several factors reported to be helpful around the time of scans were having experienced (81%) and friendly (88%) staff conducting the scan procedures, knowing what to expect about the procedures (82%), and undergoing the scan at a familiar location (i.e., close to home or at the center they received treatment, 71%). Around the time of receiving scan results, several factors reported to be helpful were the availability of scan results at the time of their oncologist appointment (91%), receipt of results from their oncologist in clinic (90%), and discussing the treatment plan in the same visit (81%) [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>].</p></sec><sec id="sec3dot6dot6-cancers-15-01381"><title>3.6.6. Psychological and Behavioral Characteristics</title><p>Some articles indicated that scanxiety was more common among those with certain baseline psychological factors. Those with higher general anxiety symptoms and fear of cancer progression were more likely to endorse experiencing scanxiety [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]. General anxiety symptoms were also associated with patients&#x02019; ratings of peak anxiety around the time of the scan [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>] and distress on the day of imaging [<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>]. In a study of people with bladder cancer, those with higher baseline anxiety also had higher anxiety following the cystoscopy procedure [<xref rid="B23-cancers-15-01381" ref-type="bibr">23</xref>]. On the other hand, this relationship was not observed between elevated general anxiety and worry about medical imaging radiation [<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>]. The likelihood of reporting scanxiety in the context of a recent scan did not differ for those with and without clinical depression [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]. In a daily diary study, patients with higher threat sensitivity (i.e., a tendency to have stronger responses to threatening cues or situations) had higher fear of cancer recurrence on the day of their mammogram and slower rates of recovery (decreases in fear of cancer recurrence) following the mammogram than those with lower threat sensitivity [<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>].</p><p>Other articles examined how health behaviors and coping strategies were related to scanxiety. For example, people who searched for information prior to their scan did not have higher levels of anxiety compared to those who did not [<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>]. In bladder cancer patients, low perceived control over the procedures was noted, and the ability to watch the procedure in real time was noted to help improve feelings of control [<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>]. Empowerment or self-efficacy in managing their health by undergoing the procedure was noted as a positive factor [<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>]. However, in a trial testing a self-management approach following treatment for endometrial cancer, women randomized to patient-initiated follow-up (self-referral if alarming symptoms occurred) had smaller decreases in fear of recurrence compared to control participants receiving regularly-scheduled hospital-based follow-up [<xref rid="B43-cancers-15-01381" ref-type="bibr">43</xref>]. Articles also summarized ways of coping; patients reported using a wide range of strategies, including distraction, relaxation, positive self-talk, and self-management of care [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>] to tolerate scans and manage scanxiety. Among post-treatment breast cancer survivors, greater confidence in one&#x02019;s ability to cope with potential recurrence was associated with lower fear of recurrence around surveillance [<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>]. Following a PET-CT scan, state anxiety scores were lower among cancer patients who were assigned to listen to music immediately before a PET-CT scan compared to those assigned to a control condition [<xref rid="B48-cancers-15-01381" ref-type="bibr">48</xref>].</p><p>Several articles examined how social relationships were associated with scanxiety. Although emotional and instrumental social support were not associated with pre-scan distress, patients who reported greater social isolation had higher distress on the day of their imaging compared to their socially connected counterparts [<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>]. In a dyadic design using daily diary methods, partner responsiveness (i.e., the degree to which one perceives their partner to respond with genuine interest and care) and capitalization attempts (i.e., the process of sharing good news with one&#x02019;s partner) were not related to fear of cancer recurrence before a mammogram [<xref rid="B28-cancers-15-01381" ref-type="bibr">28</xref>]. Contrary to hypotheses, patients whose partners were more responsive had higher fear of cancer recurrence on the day of the mammogram than those with whose partners were less responsive [<xref rid="B28-cancers-15-01381" ref-type="bibr">28</xref>].</p></sec></sec></sec><sec sec-type="discussion" id="sec4-cancers-15-01381"><title>4. Discussion</title><p>In this scoping review, we identified and synthesized findings from 36 articles on scanxiety among adults diagnosed with current or prior cancer. The articles included a notable breadth of individuals across cancer types, disease status, and stage, suggesting that scanxiety occurs across the cancer continuum. Our synthesis indicated that there are various components of the scan experience that prompt anxiety, which may differ across individuals. These components appear to cluster around aspects of the scan procedure itself and around the uncertainty associated with high-stakes results. The waiting period between the scan procedure and receipt of the results was described as particularly stressful, although few quantitative articles captured this period of time or described how results were delivered. Our review also summarized the measures and methods used in scanxiety research. The assessment tools used to measure scanxiety varied widely, with 28 unique assessment tools, and often relied on newly-created single items for study-specific purposes. While this leads to a rich literature to examine scanxiety from different angles, this variation limits conclusions about levels or consistent factors relating to scanxiety. Strengths of our approach include the large literature base screened and reviewed, the inclusion of both quantitative and qualitative research designs, and the focus on cancer survivorship. Although comprehensive searches were conducted in July 2020 and March 2021, an adjusted search approach limited to Pubmed was conducted for the final period of this review (March 2021 to July 2022), a limitation. Below, we discuss how the findings of this review could be used to inform future research directions and to generate hypotheses and approaches for interventions (<xref rid="cancers-15-01381-t005" ref-type="table">Table 5</xref>).</p><sec id="sec4dot1-cancers-15-01381"><title>4.1. Current Research Findings, Methods, and Gaps</title><p>Conceptual clarity varied across articles. Few articles provided a specific definition of scanxiety. This may have been because research questions on scanxiety were often secondary to other study aims. With limited conceptual clarity, it is not surprising that many different survey measures were used, with little harmonization across articles. To advance the science of scanxiety, there is a need to examine how it relates to closely-related constructs that may be exacerbated around scans, such as fear of recurrence or progression, anticipatory anxiety, and state anxiety. Determining if these constructs are largely the same, strongly correlated, or composed of different components would help to harmonize measurement strategies for indexing anxiety around scans. Because precise measurement methods are especially needed for assessing the impact of interventions, a strong interim approach might be to utilize measures that are worded specifically in reference to a scan (<xref rid="cancers-15-01381-t002" ref-type="table">Table 2</xref>), such as the Impact of Events Scale (six items) and the modified Distress Thermometer.</p><p>Relatedly, neighboring literature on anxiety while awaiting other types of tests (e.g., blood tests) or routine follow-up examinations should be evaluated to determine if experiences are similar during these waiting periods. For example, many patients receive key prognostic information about their disease from blood tests such as carginoembryonic antigen (CEA), prostate-specific antigen (PSA), or cancer antigen 125 (CA125) levels. As technology becomes more sophisticated, additional blood tests (e.g., cell-free DNA, or &#x0201c;liquid biopsy&#x0201d; for mutational analysis of tumors) bring with them the potential for additional distress to patients. The extent to which similar processes of heightened anxiety and uncertainty occur around these types of tests is needed. Based on the definitions and elements of scanxiety from our review, we suggest that this experience may not be limited to scans, but instead may occur in the context of other types of follow-up tests that involve uncomfortable procedures, waiting for results, and uncertainty around implications for disease status. During the article screening process, we identified articles that focused on different types of tests or follow-up without mention of imaging, but we did not review these articles based on our research objectives and inclusion criteria. Because the search terms were designed to focus on imaging-related articles, our review of literature on other testing methods would not have been comprehensive or representative. However, we identified additional articles that could be relevant to the concepts raised here, an area for future work. Findings might also inform considerations for administering existing measures or developing new ones. For example, measures or terminology that apply to anticipatory anxiety around multiple types of tests may be needed. Scanxiety is currently used to describe these processes specifically around scans, and we are not aware of broader terms that encompass anxiety around new or alternative tests that result in similar prognostic information.</p><p>The characteristics of the samples and designs in our review also point to areas in which research can be extended. For example, most of the current scanxiety literature focuses on those with solid tumors, and fewer articles included individuals with hematological malignancies. In addition, articles typically focused on individuals who were undergoing routine, scheduled scans to detect progression, treatment response, or recurrence. Only one study included individuals who were undergoing investigative scans due to new symptoms, but it seems that anxiety would likely be even higher in this context. Third, scanxiety among family members/care partners has been under-studied. Research is needed to determine their anxiety levels and needs for psychosocial support, and interactions between these factors and the patient&#x02019;s experience around the time of scans. Broader literature suggests that family members&#x02019;/care partners&#x02019; general anxiety is significant and can be higher than patients&#x02019; anxiety [<xref rid="B49-cancers-15-01381" ref-type="bibr">49</xref>,<xref rid="B50-cancers-15-01381" ref-type="bibr">50</xref>], so it is possible that periods around scans are even more stressful for them. Another future direction is to determine how delivery of scan results may impact scanxiety, especially in the context of newer formats such as direct release through patient portals [<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>,<xref rid="B51-cancers-15-01381" ref-type="bibr">51</xref>]. Given that a common focus of scanxiety was on what the scan results showed, additional research that examines how results are delivered and what they showed would be useful. These details about results delivery were rarely included in the articles reviewed, with several exceptions [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>,<xref rid="B47-cancers-15-01381" ref-type="bibr">47</xref>]. Finally, research addressing how scanxiety affects day-to-day life, clinical experiences, and follow-up care receipt is limited. Because existing articles highlighted that scanxiety drives some patients to seek greater follow-up care and others to seek less, there is a need for research to test &#x0201c;for whom&#x0201d; and &#x0201c;how&#x0201d; scanxiety affects follow-up care. Both patterns can be problematic but likely require different management strategies.</p><p>Our review also highlights areas for methodological improvements in scanxiety research. For example, psychometrics of quantitative measures were rarely provided. Overall, the description of timing of measurements with respect to the scan procedure and the results delivery could also be improved. Longitudinal assessments often included pre- and post-scan time points, but it was often unclear when scan results were delivered with respect to the post-scan assessment. To the extent possible in a given study design, it would be useful to report the nature of the test results as well as whether, when, and how results were delivered. Prospective designs that captured the period between the scan procedure and receipt of the results were especially limited. Future research on this time period is needed, given that it was identified as the most stressful by patients in qualitative articles. In addition, methods that allow for repeated measures around these times, such as daily diary designs or ecological momentary assessment, could help to elucidate fluctuating patterns of anxiety over time with respect to these events. While these methods are acceptable and feasible in young survivors of childhood cancer around the time of scans [<xref rid="B52-cancers-15-01381" ref-type="bibr">52</xref>], evaluating their acceptability and feasibility during these time periods in older survivors and those with active disease would be useful.</p><p>Based on our experience with the screening phase of this project, description of the components of clinical follow-up procedures could be improved in future articles. Some of the screened abstracts and articles had a focus on routine follow-up, but did not describe what procedures were included in these visits, or whether they involved scans or other types of tests. We excluded these articles if scans were not mentioned. However, operationalizing the types of tests or procedures in regular follow-up could potentially expand the pool of scanxiety articles available to draw upon. Accordingly, it is possible that the group of available articles is actually larger than what was reviewed here. In addition, in the broader cancer literature on anxiety and stress, it is possible that symptoms are assessed at the time of tests or follow-up visits while awaiting results, and thus affected by scanxiety. Future work on anxiety could be advanced by including questions about whether participants are awaiting upcoming tests, scans, or follow-up care to help interpret fluctuations in anxiety.</p></sec><sec id="sec4dot2-cancers-15-01381"><title>4.2. Promising Approaches to Intervention</title><p>To develop and test interventions for scanxiety, a key step is to learn which individuals are most at risk for scanxiety. While more research is needed and findings were not always consistent, our review indicated that women and those with lower education levels, shorter time since diagnosis, and greater levels of baseline anxiety may be more likely to experience scanxiety, while associations with other factors were less consistent. If these patterns hold true in future research, this information could be used to emphasize the inclusion of these individuals in the intervention development process, tailor strategies to their needs, and prioritize them for intervention delivery. For example, screening for baseline characteristics (e.g., general anxiety or fear of recurrence) could be used to inform which patients may be likely to need or benefit from additional support around the time of scans. Future research supporting these patterns could also inform intervention components. For example, it is possible that helping patients manage high levels of general anxiety could have a positive impact on their scan-specific anxiety. However, we did not analyze these patterns using meta-analysis, and the measures and time points examined were quite heterogeneous. Given these limitations, our synthesis can be used to generate hypotheses rather than to draw firm conclusions on whether these factors are related to higher scanxiety. Further research is needed to determine which patients may be most prone to increases in anxiety around the time of scans.</p><p>Few articles examined modifiable or theory-driven individual-level factors to inform intervention targets that mitigate scanxiety, another area for future work. Nevertheless, the existing literature can be used to identify promising intervention approaches. For example, a study of post-treatment breast cancer survivors investigated whether factors from the cognitive-behavioral model were related to anxiety. Women who were more confident in their ability to cope with potential recurrence experienced lower fear of cancer recurrence around their surveillance mammograms than those with lower coping self-efficacy [<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>]. These findings suggest that interventions to strengthen peoples&#x02019; coping skills for how they might handle the potential &#x0201c;bad news&#x0201d; of recurrence might be useful, as opposed to reassuring oneself that risk is low (which was associated with greater anxiety in the study). Because the waiting period before receiving results is often uncontrollable and described as the most stressful period, strategies to pass the time during this difficult window might be especially useful. For example, advanced cancer patients described using strategies such as distraction and pleasant activities to cope with scanxiety [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>]. Similarly, engaging in enjoyable flow activities that fully occupy one&#x02019;s mind could make the waiting period more tolerable [<xref rid="B53-cancers-15-01381" ref-type="bibr">53</xref>].</p><p>When developing and testing interventions, researchers should consider that anxiety may center around the scan procedures themselves, around the uncertainty associated with what the results may show, or both. It is likely that different types of intervention strategies may be needed to address these various components effectively. For example, a patient who is primarily concerned about the procedure due to claustrophobia may benefit from cognitive behavioral therapy, including exposure exercises. This approach would likely be ineffective and inappropriate for someone whose primary concern is the uncertainty of results. Short interventions around the time of scans, including real-time strategies employed in the waiting area or during scan time, may be beneficial and acceptable for those with procedural anxiety. Just-in-time micro-interventions represent a promising approach that may be well suited for these moments [<xref rid="B54-cancers-15-01381" ref-type="bibr">54</xref>]. On the other hand, a common focus of scanxiety is the ongoing uncertainty associated with the possibility of recurrence or progression, or anxiety-provoking reminders of initial diagnosis. Interventions that are employed outside of the scan procedure itself, perhaps in the lead-up to the scan or emphasized during the waiting period between the scan and results receipt, may be better suited to address anxiety arising from uncertainty about the results. In this case, people may be expected to benefit from interventions that promote meaningful engagement in activities, mindful awareness, coping with fear of progression or recurrence, or acceptance-based strategies. As research on the most beneficial strategies to support those with scanxiety emerges, a helpful approach could be to offer several different evidence-based stress management tools [<xref rid="B35-cancers-15-01381" ref-type="bibr">35</xref>], such that patients may practice those that resonate most with them.</p><p>This review also suggests that addressing clinic- and system-level factors could help mitigate scanxiety. For example, findings from qualitative articles repeatedly suggested that wait times, especially the waiting period between the scan procedure and receipt of the results, was particularly anxiety-provoking for patients. Shortening wait times to results could shorten periods of heightened anxiety for patients. Strategies that improve patients&#x02019; ability to know what to expect, such as implementing a set routine for results delivery or pre-scheduling discussion appointments, may also be useful. While the direct release of results via patient portals may provide a way to shorten wait times, data also indicates that some patients experience heightened anxiety or confusion around technical terms when viewing these results independently; thus, they may benefit from additional support, education, or informed decision-making to determine if this is the right approach for them [<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>,<xref rid="B37-cancers-15-01381" ref-type="bibr">37</xref>,<xref rid="B51-cancers-15-01381" ref-type="bibr">51</xref>]. Other patients may benefit from addressing aspects of the scan procedure itself. Improving the scan experience (e.g., by making adjustments that reduce pain or discomfort) could help to alleviate procedural anxiety. Finally, clinicians may benefit from considering which patients could struggle most with scanxiety. Shared decision-making with such patients (e.g., considering a longer interval to the next scan) as well as communicating about how to act on (e.g., anticipated treatment decisions based on results) and cope with (e.g., by voicing unending support for the patient no matter what the results, offering additional psychosocial supports as available) the potential results are other promising directions for future research and clinical practice.</p></sec></sec><sec sec-type="conclusions" id="sec5-cancers-15-01381"><title>5. Conclusions</title><p>Our review&#x02014;which involved screening and reviewing a large literature base, included quantitative and qualitative research designs, and focused on cancer survivorship&#x02014;provides insight on the nature of scanxiety, research practices and gaps, and promising strategies for interventions. In summary, scanxiety occurs across the cancer continuum. It may focus on procedural or uncertainty-related components of the scan experience. Future work to determine the ideal measurement strategies and timing of assessments would advance the current understanding of scanxiety and intervention approaches to help manage it. Efforts to harmonize measures, examine the waiting period between scans and scan results, and identify intervention targets are particularly needed. Emerging literature indicates that some individuals may be more prone to elevated anxiety around the time of scans, and suggests promising approaches at the individual and clinic/system levels to help manage scanxiety. Given that scan experiences are common and repeated across the cancer continuum, strategies to support patients around these times have the potential to improve quality of life and other outcomes for those living with and beyond cancer.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-cancers-15-01381"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/cancers15051381/s1">https://www.mdpi.com/article/10.3390/cancers15051381/s1</uri>, File S1: OVID Search Strategy.</p><supplementary-material id="cancers-15-01381-s001" position="float" content-type="local-data"><media xlink:href="cancers-15-01381-s001.zip"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization: H.M.D.-V. and L.C.H.; Methodology: H.M.D.-V., L.C.H., and J.S.; Data Curation: H.M.D.-V.; Project Administration: H.M.D.-V., L.C.H., N.G., M.L.; Interpretation: H.M.D.-V., L.C.H., N.G., J.S., M.L., A.S.E., H.G.P.; Writing&#x02014;Original Draft Preparation: H.M.D.-V.; Writing&#x02014;Review and Editing: H.M.D.-V., L.C.H., N.G., J.S., M.L., A.S.E., H.G.P.; Resources: H.M.D.-V. and H.G.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>H.M.D.V. discloses a financial relationship (immediate family member) with Dechra. A.S.E. discloses royalties from reviewing UpToDate topics on gastrointestinal cancers, medical oncology, and palliative care.</p></notes><ref-list><title>References</title><ref id="B1-cancers-15-01381"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feiler</surname><given-names>B.</given-names></name>
</person-group><article-title>Scanxiety. Fear of a postcancer ritual</article-title><source>Time</source><year>2011</year><volume>177</volume><fpage>56</fpage><pub-id pub-id-type="pmid">21682131</pub-id></element-citation></ref><ref id="B2-cancers-15-01381"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bui</surname><given-names>K.T.</given-names></name>
<name><surname>Blinman</surname><given-names>P.</given-names></name>
<name><surname>Kiely</surname><given-names>B.E.</given-names></name>
<name><surname>Brown</surname><given-names>C.</given-names></name>
<name><surname>Dhillon</surname><given-names>H.M.</given-names></name>
</person-group><article-title>Experiences with scans and scanxiety in people with advanced cancer: A qualitative study</article-title><source>Support Care Cancer</source><year>2021</year><volume>29</volume><fpage>7441</fpage><lpage>7449</lpage><pub-id pub-id-type="doi">10.1007/s00520-021-06319-1</pub-id><pub-id pub-id-type="pmid">34076779</pub-id></element-citation></ref><ref id="B3-cancers-15-01381"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bauml</surname><given-names>J.M.</given-names></name>
<name><surname>Troxel</surname><given-names>A.</given-names></name>
<name><surname>Epperson</surname><given-names>C.N.</given-names></name>
<name><surname>Cohen</surname><given-names>R.B.</given-names></name>
<name><surname>Schmitz</surname><given-names>K.</given-names></name>
<name><surname>Stricker</surname><given-names>C.</given-names></name>
<name><surname>Shulman</surname><given-names>L.N.</given-names></name>
<name><surname>Bradbury</surname><given-names>A.</given-names></name>
<name><surname>Mao</surname><given-names>J.J.</given-names></name>
<name><surname>Langer</surname><given-names>C.J.</given-names></name>
</person-group><article-title>Scan-associated distress in lung cancer: Quantifying the impact of &#x0201c;scanxiety&#x0201d;</article-title><source>Lung Cancer</source><year>2016</year><volume>100</volume><fpage>110</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2016.08.002</pub-id><pub-id pub-id-type="pmid">27597289</pub-id></element-citation></ref><ref id="B4-cancers-15-01381"><label>4.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Hurley-Browning</surname><given-names>L.</given-names></name>
</person-group><article-title>What Is Scanxiety? Abramson Cancer Center&#x02014;Penn Medicine</article-title><year>2018</year><comment>Available online: <ext-link xlink:href="https://www.pennmedicine.org/cancer/about/focus-on-cancer/2018/october/what-is-scanxiety" ext-link-type="uri">https://www.pennmedicine.org/cancer/about/focus-on-cancer/2018/october/what-is-scanxiety</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-16">(accessed on 16 December 2022)</date-in-citation></element-citation></ref><ref id="B5-cancers-15-01381"><label>5.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Darisipudi</surname><given-names>S.</given-names></name>
</person-group><article-title>Tools Patients, Survivors and Cancer Caregivers Use to Deal With &#x02018;Scanxiety&#x02019;. Cure Today</article-title><comment>Available online: <ext-link xlink:href="https://www.curetoday.com/view/tools-patients-survivors-and-cancer-caregivers-use-to-deal-with-scanxiety-" ext-link-type="uri">https://www.curetoday.com/view/tools-patients-survivors-and-cancer-caregivers-use-to-deal-with-scanxiety-</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-16">(accessed on 16 December 2022)</date-in-citation></element-citation></ref><ref id="B6-cancers-15-01381"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peteet</surname><given-names>J.R.</given-names></name>
<name><surname>Stomper</surname><given-names>P.C.</given-names></name>
<name><surname>Ross</surname><given-names>D.M.</given-names></name>
<name><surname>Cotton</surname><given-names>V.</given-names></name>
<name><surname>Truesdell</surname><given-names>P.</given-names></name>
<name><surname>Moczynski</surname><given-names>W.</given-names></name>
</person-group><article-title>Emotional support for patients with cancer who are undergoing CT: Semistructured interviews of patients at a cancer institute</article-title><source>Radiology</source><year>1992</year><volume>182</volume><fpage>99</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1148/radiology.182.1.1727318</pub-id><pub-id pub-id-type="pmid">1727318</pub-id></element-citation></ref><ref id="B7-cancers-15-01381"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mollica</surname><given-names>M.A.</given-names></name>
<name><surname>Smith</surname><given-names>A.W.</given-names></name>
<name><surname>Tonorezos</surname><given-names>E.</given-names></name>
<name><surname>Castro</surname><given-names>K.</given-names></name>
<name><surname>Filipski</surname><given-names>K.K.</given-names></name>
<name><surname>Guida</surname><given-names>J.</given-names></name>
<name><surname>Perna</surname><given-names>F.</given-names></name>
<name><surname>Green</surname><given-names>P.</given-names></name>
<name><surname>Jacobsen</surname><given-names>P.B.</given-names></name>
<name><surname>Mariotto</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Survivorship for Individuals Living With Advanced and Metastatic Cancers: National Cancer Institute Meeting Report</article-title><source>JNCI J. Natl. Cancer Inst.</source><year>2022</year><volume>114</volume><fpage>489</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1093/jnci/djab223</pub-id><pub-id pub-id-type="pmid">34878107</pub-id></element-citation></ref><ref id="B8-cancers-15-01381"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bui</surname><given-names>K.T.</given-names></name>
<name><surname>Liang</surname><given-names>R.</given-names></name>
<name><surname>Kiely</surname><given-names>B.E.</given-names></name>
<name><surname>Brown</surname><given-names>C.</given-names></name>
<name><surname>Dhillon</surname><given-names>H.M.</given-names></name>
<name><surname>Blinman</surname><given-names>P.</given-names></name>
</person-group><article-title>Scanxiety: A scoping review about scan-associated anxiety</article-title><source>BMJ Open</source><year>2021</year><volume>11</volume><fpage>e043215</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2020-043215</pub-id></element-citation></ref><ref id="B9-cancers-15-01381"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Munn</surname><given-names>Z.</given-names></name>
<name><surname>Peters</surname><given-names>M.D.J.</given-names></name>
<name><surname>Stern</surname><given-names>C.</given-names></name>
<name><surname>Tufanaru</surname><given-names>C.</given-names></name>
<name><surname>McArthur</surname><given-names>A.</given-names></name>
<name><surname>Aromataris</surname><given-names>E.</given-names></name>
</person-group><article-title>Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach</article-title><source>BMC Med. Res. Methodol.</source><year>2018</year><volume>18</volume><elocation-id>143</elocation-id><pub-id pub-id-type="doi">10.1186/s12874-018-0611-x</pub-id><pub-id pub-id-type="pmid">30453902</pub-id></element-citation></ref><ref id="B10-cancers-15-01381"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tricco</surname><given-names>A.C.</given-names></name>
<name><surname>Lillie</surname><given-names>E.</given-names></name>
<name><surname>Zarin</surname><given-names>W.</given-names></name>
<name><surname>O&#x02019;Brien</surname><given-names>K.K.</given-names></name>
<name><surname>Colquhoun</surname><given-names>H.</given-names></name>
<name><surname>Levac</surname><given-names>D.</given-names></name>
<name><surname>Moher</surname><given-names>D.</given-names></name>
<name><surname>Peters</surname><given-names>M.D.J.</given-names></name>
<name><surname>Horsley</surname><given-names>T.</given-names></name>
<name><surname>Weeks</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation</article-title><source>Ann. Intern. Med.</source><year>2018</year><volume>169</volume><fpage>467</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.7326/M18-0850</pub-id><pub-id pub-id-type="pmid">30178033</pub-id></element-citation></ref><ref id="B11-cancers-15-01381"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peters</surname><given-names>M.D.J.</given-names></name>
<name><surname>Marnie</surname><given-names>C.</given-names></name>
<name><surname>Tricco</surname><given-names>A.C.</given-names></name>
<name><surname>Pollock</surname><given-names>D.</given-names></name>
<name><surname>Munn</surname><given-names>Z.</given-names></name>
<name><surname>Alexander</surname><given-names>L.</given-names></name>
<name><surname>McInerney</surname><given-names>P.</given-names></name>
<name><surname>Godfrey</surname><given-names>C.M.</given-names></name>
<name><surname>Khalil</surname><given-names>H.</given-names></name>
</person-group><article-title>Updated methodological guidance for the conduct of scoping reviews</article-title><source>JBI Evid. Synth.</source><year>2020</year><volume>18</volume><fpage>2119</fpage><lpage>2126</lpage><pub-id pub-id-type="doi">10.11124/JBIES-20-00167</pub-id><pub-id pub-id-type="pmid">33038124</pub-id></element-citation></ref><ref id="B12-cancers-15-01381"><label>12.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Derry-Vick</surname><given-names>H.M.</given-names></name>
<name><surname>Heathcote</surname><given-names>L.C.</given-names></name>
<name><surname>Stribling</surname><given-names>J.</given-names></name>
<name><surname>Glesby</surname><given-names>N.</given-names></name>
<name><surname>Luebke</surname><given-names>M.</given-names></name>
<name><surname>Epstein</surname><given-names>A.S.</given-names></name>
<name><surname>Prigerson</surname><given-names>H.G.</given-names></name>
</person-group><article-title>Scan-Related Anxiety among Adults with Cancer: A Scoping Review Protocol</article-title><year>2021</year><comment>Available online: <ext-link xlink:href="https://osf.io/b52y8/" ext-link-type="uri">https://osf.io/b52y8/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-03-29">(accessed on 29 March 2021)</date-in-citation></element-citation></ref><ref id="B13-cancers-15-01381"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grilo</surname><given-names>A.</given-names></name>
<name><surname>Vieira</surname><given-names>L.</given-names></name>
<name><surname>Carolino</surname><given-names>E.</given-names></name>
<name><surname>Oliveira</surname><given-names>C.</given-names></name>
<name><surname>Pacheco</surname><given-names>C.</given-names></name>
<name><surname>Castro</surname><given-names>M.</given-names></name>
<name><surname>Alonso</surname><given-names>J.</given-names></name>
</person-group><article-title>Anxiety in Cancer Patients during 18F-FDG PET/CT Low Dose: A Comparison of Anxiety Levels before and after Imaging Studies</article-title><source>Nurs. Res. Pract.</source><year>2017</year><volume>2017</volume><fpage>3057495</fpage><pub-id pub-id-type="doi">10.1155/2017/3057495</pub-id><pub-id pub-id-type="pmid">28392942</pub-id></element-citation></ref><ref id="B14-cancers-15-01381"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McGinty</surname><given-names>H.L.</given-names></name>
<name><surname>Small</surname><given-names>B.J.</given-names></name>
<name><surname>Laronga</surname><given-names>C.</given-names></name>
<name><surname>Jacobsen</surname><given-names>P.B.</given-names></name>
</person-group><article-title>Predictors and patterns of fear of cancer recurrence in breast cancer survivors</article-title><source>Health Psychol.</source><year>2016</year><volume>35</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1037/hea0000238</pub-id><pub-id pub-id-type="pmid">26030308</pub-id></element-citation></ref><ref id="B15-cancers-15-01381"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morreale</surname><given-names>M.K.</given-names></name>
<name><surname>Moore</surname><given-names>T.F.</given-names></name>
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Uphold</surname><given-names>H.S.</given-names></name>
<name><surname>Mabunda</surname><given-names>L.M.</given-names></name>
<name><surname>Harper</surname><given-names>F.W.K.</given-names></name>
</person-group><article-title>Preferences for notification of imaging results in patients with metastatic cancer</article-title><source>Patient Educ. Couns.</source><year>2020</year><volume>103</volume><fpage>392</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1016/j.pec.2019.08.032</pub-id><pub-id pub-id-type="pmid">31466880</pub-id></element-citation></ref><ref id="B16-cancers-15-01381"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>H.D.</given-names></name>
<name><surname>Riffon</surname><given-names>M.F.</given-names></name>
<name><surname>Joice</surname><given-names>G.A.</given-names></name>
<name><surname>Johnson</surname><given-names>M.H.</given-names></name>
<name><surname>Chang</surname><given-names>P.</given-names></name>
<name><surname>Wagner</surname><given-names>A.A.</given-names></name>
<name><surname>McKiernan</surname><given-names>J.M.</given-names></name>
<name><surname>Trock</surname><given-names>B.J.</given-names></name>
<name><surname>Allaf</surname><given-names>M.E.</given-names></name>
<name><surname>Pierorazio</surname><given-names>P.M.</given-names></name>
</person-group><article-title>A Prospective, Comparative Study of Quality of Life among Patients with Small Renal Masses Choosing Active Surveillance and Primary Intervention</article-title><source>J. Urol.</source><year>2016</year><volume>196</volume><fpage>1356</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2016.04.073</pub-id><pub-id pub-id-type="pmid">27140071</pub-id></element-citation></ref><ref id="B17-cancers-15-01381"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koinis</surname><given-names>F.</given-names></name>
<name><surname>Leontopoulou</surname><given-names>V.</given-names></name>
<name><surname>Chantzara</surname><given-names>E.</given-names></name>
<name><surname>Kotsakis</surname><given-names>A.</given-names></name>
</person-group><article-title>&#x0201c;The Oizys Study&#x0201d;: Prevalence and impact of scan-related anxiety on QoL among Greek cancer patients and their caregivers</article-title><source>JCO</source><year>2022</year><volume>40</volume><fpage>e24118</fpage><pub-id pub-id-type="doi">10.1200/JCO.2022.40.16_suppl.e24118</pub-id></element-citation></ref><ref id="B18-cancers-15-01381"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>C.A.</given-names></name>
<name><surname>Charlson</surname><given-names>M.E.</given-names></name>
<name><surname>Schenkein</surname><given-names>E.</given-names></name>
<name><surname>Wells</surname><given-names>M.T.</given-names></name>
<name><surname>Furman</surname><given-names>R.R.</given-names></name>
<name><surname>Elstrom</surname><given-names>R.</given-names></name>
<name><surname>Ruan</surname><given-names>J.</given-names></name>
<name><surname>Martin</surname><given-names>P.</given-names></name>
<name><surname>Leonard</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors</article-title><source>Ann. Oncol.</source><year>2010</year><volume>21</volume><fpage>2262</fpage><lpage>2266</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdq215</pub-id><pub-id pub-id-type="pmid">20423914</pub-id></element-citation></ref><ref id="B19-cancers-15-01381"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Wiedemann</surname><given-names>K.</given-names></name>
</person-group><article-title>Anxiety and Anxiety Disorders</article-title><source>International Encyclopedia of the Social &#x00026; Behavioral Sciences</source><person-group person-group-type="editor">
<name><surname>Smelser</surname><given-names>N.J.</given-names></name>
<name><surname>Baltes</surname><given-names>P.B.</given-names></name>
</person-group><publisher-name>Pergamon</publisher-name><publisher-loc>Oxford, UK</publisher-loc><year>2001</year><fpage>560</fpage><lpage>567</lpage><isbn>978-0-08-043076-8</isbn></element-citation></ref><ref id="B20-cancers-15-01381"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lo Re</surname><given-names>G.</given-names></name>
<name><surname>De Luca</surname><given-names>R.</given-names></name>
<name><surname>Muscarneri</surname><given-names>F.</given-names></name>
<name><surname>Dorangricchia</surname><given-names>P.</given-names></name>
<name><surname>Picone</surname><given-names>D.</given-names></name>
<name><surname>Vernuccio</surname><given-names>F.</given-names></name>
<name><surname>Salerno</surname><given-names>S.</given-names></name>
<name><surname>La Tona</surname><given-names>G.</given-names></name>
<name><surname>Pinto</surname><given-names>A.</given-names></name>
<name><surname>Midiri</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Relationship between anxiety level and radiological investigation. Comparison among different diagnostic imaging exams in a prospective single-center study</article-title><source>Radiol. Med.</source><year>2016</year><volume>121</volume><fpage>763</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1007/s11547-016-0664-z</pub-id><pub-id pub-id-type="pmid">27334010</pub-id></element-citation></ref><ref id="B21-cancers-15-01381"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abreu</surname><given-names>C.</given-names></name>
<name><surname>Grilo</surname><given-names>A.</given-names></name>
<name><surname>Lucena</surname><given-names>F.</given-names></name>
<name><surname>Carolino</surname><given-names>E.</given-names></name>
</person-group><article-title>Oncological Patient Anxiety in Imaging Studies: The PET/CT Example</article-title><source>J. Cancer Educ.</source><year>2017</year><volume>32</volume><fpage>820</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1007/s13187-016-1069-3</pub-id><pub-id pub-id-type="pmid">27370917</pub-id></element-citation></ref><ref id="B22-cancers-15-01381"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cox</surname><given-names>C.L.</given-names></name>
<name><surname>Zhu</surname><given-names>L.</given-names></name>
<name><surname>Hudson</surname><given-names>M.M.</given-names></name>
<name><surname>Steen</surname><given-names>B.D.</given-names></name>
<name><surname>Robison</surname><given-names>L.L.</given-names></name>
<name><surname>Oeffinger</surname><given-names>K.C.</given-names></name>
</person-group><article-title>Survivor typologies predict medical surveillance participation: The childhood cancer survivor study</article-title><source>Psycho-Oncol.</source><year>2013</year><volume>22</volume><fpage>1534</fpage><lpage>1542</lpage><pub-id pub-id-type="doi">10.1002/pon.3167</pub-id><pub-id pub-id-type="pmid">22968964</pub-id></element-citation></ref><ref id="B23-cancers-15-01381"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krajewski</surname><given-names>W.</given-names></name>
<name><surname>Koscielska-Kasprzak</surname><given-names>K.</given-names></name>
<name><surname>Rymaszewska</surname><given-names>J.</given-names></name>
<name><surname>Zdrojowy</surname><given-names>R.</given-names></name>
</person-group><article-title>How different cystoscopy methods influence patient sexual satisfaction, anxiety, and depression levels: A randomized prospective trial</article-title><source>Qual. Life Res.</source><year>2017</year><volume>26</volume><fpage>625</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1007/s11136-016-1493-1</pub-id><pub-id pub-id-type="pmid">28050795</pub-id></element-citation></ref><ref id="B24-cancers-15-01381"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McGinty</surname><given-names>H.</given-names></name>
<name><surname>Laronga</surname><given-names>C.</given-names></name>
<name><surname>Hicks</surname><given-names>C.</given-names></name>
<name><surname>Cases</surname><given-names>M.</given-names></name>
<name><surname>Rose</surname><given-names>M.</given-names></name>
<name><surname>Rodriguez</surname><given-names>Y.</given-names></name>
<name><surname>Jacobsen</surname><given-names>P.</given-names></name>
</person-group><article-title>Sleep quality before and after surveillance mammograms in breast cancer survivors: Fear of cancer recurrence predicts longitudinal change in sleep quality</article-title><source>Psycho-Oncol.</source><year>2014</year><volume>1</volume><fpage>4</fpage><lpage>5</lpage></element-citation></ref><ref id="B25-cancers-15-01381"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Porter</surname><given-names>L.S.</given-names></name>
<name><surname>Mishel</surname><given-names>M.</given-names></name>
<name><surname>Neelon</surname><given-names>V.</given-names></name>
<name><surname>Belyea</surname><given-names>M.</given-names></name>
<name><surname>Pisano</surname><given-names>E.</given-names></name>
<name><surname>Soo</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Cortisol levels and responses to mammography screening in breast cancer survivors: A pilot study</article-title><source>Psychosom. Med.</source><year>2003</year><volume>65</volume><fpage>842</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1097/01.PSY.0000088595.91705.C5</pub-id><pub-id pub-id-type="pmid">14508030</pub-id></element-citation></ref><ref id="B26-cancers-15-01381"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shelby</surname><given-names>R.A.</given-names></name>
<name><surname>Scipio</surname><given-names>C.D.</given-names></name>
<name><surname>Somers</surname><given-names>T.J.</given-names></name>
<name><surname>Soo</surname><given-names>M.S.</given-names></name>
<name><surname>Weinfurt</surname><given-names>K.P.</given-names></name>
<name><surname>Keefe</surname><given-names>F.J.</given-names></name>
</person-group><article-title>Prospective Study of Factors Predicting Adherence to Surveillance Mammography in Women Treated for Breast Cancer</article-title><source>J. Clin. Oncol.</source><year>2012</year><volume>30</volume><fpage>813</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.34.4333</pub-id><pub-id pub-id-type="pmid">22331949</pub-id></element-citation></ref><ref id="B27-cancers-15-01381"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soriano</surname><given-names>E.C.</given-names></name>
<name><surname>Perndorfer</surname><given-names>C.</given-names></name>
<name><surname>Siegel</surname><given-names>S.D.</given-names></name>
<name><surname>Laurenceau</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Threat sensitivity and fear of cancer recurrence: A daily diary study of reactivity and recovery as patients and spouses face the first mammogram post-diagnosis</article-title><source>J. Psychosoc. Oncol.</source><year>2019</year><volume>37</volume><fpage>131</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1080/07347332.2018.1535532</pub-id><pub-id pub-id-type="pmid">30590993</pub-id></element-citation></ref><ref id="B28-cancers-15-01381"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soriano</surname><given-names>E.C.</given-names></name>
<name><surname>Perndorfer</surname><given-names>C.</given-names></name>
<name><surname>Otto</surname><given-names>A.K.</given-names></name>
<name><surname>Siegel</surname><given-names>S.D.</given-names></name>
<name><surname>Laurenceau</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Does sharing good news buffer fear of bad news? A daily diary study of fear of cancer recurrence in couples approaching the first mammogram post-diagnosis</article-title><source>Psycho-Oncol.</source><year>2018</year><volume>27</volume><fpage>2581</fpage><lpage>2586</lpage><pub-id pub-id-type="doi">10.1002/pon.4813</pub-id><pub-id pub-id-type="pmid">29927016</pub-id></element-citation></ref><ref id="B29-cancers-15-01381"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bui</surname><given-names>K.T.</given-names></name>
<name><surname>Kiely</surname><given-names>B.E.</given-names></name>
<name><surname>Dhillon</surname><given-names>H.M.</given-names></name>
<name><surname>Brown</surname><given-names>C.</given-names></name>
<name><surname>Xu</surname><given-names>K.</given-names></name>
<name><surname>Shafiei</surname><given-names>M.</given-names></name>
<name><surname>Blinman</surname><given-names>P.</given-names></name>
</person-group><article-title>Prevalence and severity of scanxiety in people with advanced cancers: A multicentre survey</article-title><source>Support Care Cancer</source><year>2022</year><volume>30</volume><fpage>511</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1007/s00520-021-06454-9</pub-id><pub-id pub-id-type="pmid">34333717</pub-id></element-citation></ref><ref id="B30-cancers-15-01381"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koo</surname><given-names>K.</given-names></name>
<name><surname>Zubkoff</surname><given-names>L.</given-names></name>
<name><surname>Sirovich</surname><given-names>B.E.</given-names></name>
<name><surname>Goodney</surname><given-names>P.P.</given-names></name>
<name><surname>Robertson</surname><given-names>D.J.</given-names></name>
<name><surname>Seigne</surname><given-names>J.D.</given-names></name>
<name><surname>Schroeck</surname><given-names>F.R.</given-names></name>
</person-group><article-title>The Burden of Cystoscopic Bladder Cancer Surveillance: Anxiety, Discomfort, and Patient Preferences for Decision Making</article-title><source>Urology</source><year>2017</year><volume>108</volume><fpage>122</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2017.07.016</pub-id><pub-id pub-id-type="pmid">28739405</pub-id></element-citation></ref><ref id="B31-cancers-15-01381"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mannion</surname><given-names>S.</given-names></name>
<name><surname>Martin</surname><given-names>N.A.</given-names></name>
<name><surname>O&#x02019;Connor</surname><given-names>J.</given-names></name>
<name><surname>Wieland</surname><given-names>J.</given-names></name>
<name><surname>Jatoi</surname><given-names>A.</given-names></name>
</person-group><article-title>In Their Own Words, &#x0201c;Waiting Sucks:&#x0201d; A Qualitative Study of Medical Testing-Related Anxiety in Patients with Cancer</article-title><source>Am. J. Hosp. Palliat. Care</source><year>2022</year><comment>
<italic toggle="yes">online ahead of print</italic>
</comment><pub-id pub-id-type="doi">10.1177/10499091221105502</pub-id></element-citation></ref><ref id="B32-cancers-15-01381"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wernli</surname><given-names>K.</given-names></name>
<name><surname>Brandzel</surname><given-names>S.</given-names></name>
<name><surname>Buist</surname><given-names>D.</given-names></name>
<name><surname>Bush</surname><given-names>M.</given-names></name>
<name><surname>DeMartini</surname><given-names>W.</given-names></name>
<name><surname>Ichikawa</surname><given-names>L.</given-names></name>
<name><surname>Haas</surname><given-names>C.</given-names></name>
<name><surname>Henderson</surname><given-names>L.</given-names></name>
<name><surname>Johnson</surname><given-names>D.</given-names></name>
<name><surname>Kerlikowske</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Is Breast MRI Better at Finding Second Breast Cancers than Mammograms Alone for Breast Cancer Survivors?</article-title><source>Patient Cent. Outcomes Res. Inst.</source><year>2019</year><volume>05</volume><fpage>05</fpage><pub-id pub-id-type="doi">10.25302/5.2019.CE.13046656</pub-id></element-citation></ref><ref id="B33-cancers-15-01381"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pascal</surname><given-names>J.</given-names></name>
<name><surname>Endacott</surname><given-names>R.</given-names></name>
</person-group><article-title>Ethical and existential challenges associated with a cancer diagnosis</article-title><source>J. Med. Ethics</source><year>2010</year><volume>36</volume><fpage>279</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1136/jme.2009.034942</pub-id><pub-id pub-id-type="pmid">20439328</pub-id></element-citation></ref><ref id="B34-cancers-15-01381"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lai-Kwon</surname><given-names>J.</given-names></name>
<name><surname>Heynemann</surname><given-names>S.</given-names></name>
<name><surname>Flore</surname><given-names>J.</given-names></name>
<name><surname>Dhillon</surname><given-names>H.</given-names></name>
<name><surname>Duffy</surname><given-names>M.</given-names></name>
<name><surname>Burke</surname><given-names>J.</given-names></name>
<name><surname>Briggs</surname><given-names>L.</given-names></name>
<name><surname>Leigh</surname><given-names>L.</given-names></name>
<name><surname>Mileshkin</surname><given-names>L.</given-names></name>
<name><surname>Solomon</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Living with and beyond metastatic non-small cell lung cancer: The survivorship experience for people treated with immunotherapy or targeted therapy</article-title><source>J. Cancer Surviv.</source><year>2021</year><volume>15</volume><fpage>392</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1007/s11764-021-01024-8</pub-id><pub-id pub-id-type="pmid">33788170</pub-id></element-citation></ref><ref id="B35-cancers-15-01381"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Derry-Vick</surname><given-names>H.</given-names></name>
<name><surname>Hahne</surname><given-names>J.</given-names></name>
<name><surname>Saxena</surname><given-names>A.</given-names></name>
<name><surname>Glesby</surname><given-names>N.</given-names></name>
<name><surname>Epstein</surname><given-names>A.</given-names></name>
<name><surname>Lichtenthal</surname><given-names>W.G.</given-names></name>
<name><surname>Prigerson</surname><given-names>H.</given-names></name>
</person-group><article-title>Mixed methods study to inform adaptation of a stress management intervention for advanced cancer patients awaiting scan results</article-title><source>Ann. Behav. Med.</source><year>2022</year><volume>56</volume><fpage>S503</fpage></element-citation></ref><ref id="B36-cancers-15-01381"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sterba</surname><given-names>K.R.</given-names></name>
<name><surname>Zapka</surname><given-names>J.</given-names></name>
<name><surname>LaPelle</surname><given-names>N.</given-names></name>
<name><surname>Armeson</surname><given-names>K.</given-names></name>
<name><surname>Ford</surname><given-names>M.E.</given-names></name>
</person-group><article-title>A Formative Study of Colon Cancer Surveillance Care: Implications for Survivor-Centered Interventions</article-title><source>J. Cancer Educ.</source><year>2015</year><volume>30</volume><fpage>719</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1007/s13187-014-0756-1</pub-id><pub-id pub-id-type="pmid">25411092</pub-id></element-citation></ref><ref id="B37-cancers-15-01381"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baun</surname><given-names>C.</given-names></name>
<name><surname>Vogsen</surname><given-names>M.</given-names></name>
<name><surname>Nielsen</surname><given-names>M.K.</given-names></name>
<name><surname>Hoilund-Carlsen</surname><given-names>P.F.</given-names></name>
<name><surname>Hildebrandt</surname><given-names>M.G.</given-names></name>
</person-group><article-title>Perspective of Patients with Metastatic Breast Cancer on Electronic Access to Scan Results: Mixed-Methods Study</article-title><source>J. Med. Internet Res.</source><year>2020</year><volume>22</volume><fpage>e15723</fpage><pub-id pub-id-type="doi">10.2196/15723</pub-id><pub-id pub-id-type="pmid">32039819</pub-id></element-citation></ref><ref id="B38-cancers-15-01381"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hay</surname><given-names>J.L.</given-names></name>
<name><surname>Baser</surname><given-names>R.E.</given-names></name>
<name><surname>Westerman</surname><given-names>J.S.</given-names></name>
<name><surname>Ford</surname><given-names>J.S.</given-names></name>
</person-group><article-title>Prevalence and Correlates of Worry About Medical Imaging Radiation Among United States Cancer Survivors</article-title><source>Int. J. Behav. Med.</source><year>2018</year><volume>25</volume><fpage>569</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1007/s12529-018-9730-3</pub-id><pub-id pub-id-type="pmid">29872990</pub-id></element-citation></ref><ref id="B39-cancers-15-01381"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goense</surname><given-names>L.</given-names></name>
<name><surname>Borggreve</surname><given-names>A.S.</given-names></name>
<name><surname>Heethuis</surname><given-names>S.E.</given-names></name>
<name><surname>van Lier</surname><given-names>A.L.</given-names></name>
<name><surname>van Hillegersberg</surname><given-names>R.</given-names></name>
<name><surname>Mook</surname><given-names>S.</given-names></name>
<name><surname>Meijer</surname><given-names>G.J.</given-names></name>
<name><surname>van Rossum</surname><given-names>P.S.N.</given-names></name>
<name><surname>Ruurda</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Patient perspectives on repeated MRI and PET/CT examinations during neoadjuvant treatment of esophageal cancer</article-title><source>Br. J. Radiol.</source><year>2018</year><volume>91</volume><fpage>20170710</fpage><pub-id pub-id-type="doi">10.1259/bjr.20170710</pub-id><pub-id pub-id-type="pmid">29498535</pub-id></element-citation></ref><ref id="B40-cancers-15-01381"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brandzel</surname><given-names>S.</given-names></name>
<name><surname>Rosenberg</surname><given-names>D.E.</given-names></name>
<name><surname>Johnson</surname><given-names>D.</given-names></name>
<name><surname>Bush</surname><given-names>M.</given-names></name>
<name><surname>Kerlikowske</surname><given-names>K.</given-names></name>
<name><surname>Onega</surname><given-names>T.</given-names></name>
<name><surname>Henderson</surname><given-names>L.</given-names></name>
<name><surname>Nekhlyudov</surname><given-names>L.</given-names></name>
<name><surname>DeMartini</surname><given-names>W.</given-names></name>
<name><surname>Wernli</surname><given-names>K.J.</given-names></name>
</person-group><article-title>Women&#x02019;s experiences and preferences regarding breast imaging after completing breast cancer treatment</article-title><source>Patient Prefer. Adherence</source><year>2017</year><volume>11</volume><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.2147/PPA.S122244</pub-id><pub-id pub-id-type="pmid">28203064</pub-id></element-citation></ref><ref id="B41-cancers-15-01381"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bellhouse</surname><given-names>S.</given-names></name>
<name><surname>Brown</surname><given-names>S.</given-names></name>
<name><surname>Dubec</surname><given-names>M.</given-names></name>
<name><surname>Taylor</surname><given-names>S.</given-names></name>
<name><surname>Hales</surname><given-names>R.</given-names></name>
<name><surname>Whiteside</surname><given-names>L.</given-names></name>
<name><surname>Yorke</surname><given-names>J.</given-names></name>
<name><surname>Faivre-Finn</surname><given-names>C.</given-names></name>
</person-group><article-title>Introducing magnetic resonance imaging into the lung cancer radiotherapy workflow&#x02014;An assessment of patient experience</article-title><source>Radiography</source><year>2020</year><volume>22</volume><fpage>22</fpage><pub-id pub-id-type="doi">10.1016/j.radi.2020.04.020</pub-id><pub-id pub-id-type="pmid">32451307</pub-id></element-citation></ref><ref id="B42-cancers-15-01381"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bjelic-Radisic</surname><given-names>V.</given-names></name>
<name><surname>Dorfer</surname><given-names>M.</given-names></name>
<name><surname>Tamussino</surname><given-names>K.</given-names></name>
<name><surname>Greimel</surname><given-names>E.</given-names></name>
</person-group><article-title>Patients&#x02019; view of routine follow-up after breast cancer treatment</article-title><source>Wien. Klin. Wochenschr.</source><year>2017</year><volume>129</volume><fpage>810</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1007/s00508-017-1278-8</pub-id><pub-id pub-id-type="pmid">29043441</pub-id></element-citation></ref><ref id="B43-cancers-15-01381"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jeppesen</surname><given-names>M.M.</given-names></name>
<name><surname>Jensen</surname><given-names>P.T.</given-names></name>
<name><surname>Hansen</surname><given-names>D.G.</given-names></name>
<name><surname>Christensen</surname><given-names>R.D.</given-names></name>
<name><surname>Mogensen</surname><given-names>O.</given-names></name>
</person-group><article-title>Patient-initiated follow up affects fear of recurrence and healthcare use: A randomised trial in early-stage endometrial cancer</article-title><source>BJOG: Int. J. Obstet. Gynaecol.</source><year>2018</year><volume>125</volume><fpage>1705</fpage><lpage>1714</lpage><pub-id pub-id-type="doi">10.1111/1471-0528.15396</pub-id></element-citation></ref><ref id="B44-cancers-15-01381"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Allen</surname><given-names>A.</given-names></name>
</person-group><article-title>The meaning of the breast cancer follow-up experience for the women who attend</article-title><source>Eur. J. Oncol. Nurs.</source><year>2002</year><volume>6</volume><fpage>155</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1054/ejon.2002.0175</pub-id><pub-id pub-id-type="pmid">12849590</pub-id></element-citation></ref><ref id="B45-cancers-15-01381"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>H.S.</given-names></name>
<name><surname>Littles</surname><given-names>M.</given-names></name>
<name><surname>Jacob</surname><given-names>S.</given-names></name>
<name><surname>Coker</surname><given-names>C.</given-names></name>
</person-group><article-title>Cancer survivors of African descent posttreatment breast cancer surveillance and follow-up care experiences of breast&#x02014;An exploratory qualitative study</article-title><source>Cancer Nurs.</source><year>2006</year><volume>29</volume><fpage>478</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1097/00002820-200611000-00009</pub-id><pub-id pub-id-type="pmid">17135822</pub-id></element-citation></ref><ref id="B46-cancers-15-01381"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Westerterp</surname><given-names>M.</given-names></name>
<name><surname>van Westreenen</surname><given-names>H.L.</given-names></name>
<name><surname>Deutekom</surname><given-names>M.</given-names></name>
<name><surname>Stoker</surname><given-names>J.</given-names></name>
<name><surname>Fockens</surname><given-names>P.</given-names></name>
<name><surname>Comans</surname><given-names>E.F.</given-names></name>
<name><surname>Plukker</surname><given-names>J.T.</given-names></name>
<name><surname>Bossuyt</surname><given-names>P.M.</given-names></name>
<name><surname>van Lanschot</surname><given-names>J.J.</given-names></name>
<name><surname>Sloof</surname><given-names>G.W.</given-names></name>
</person-group><article-title>Patients&#x02019; perception of diagnostic tests in the preoperative assessment of esophageal cancer</article-title><source>Patient Prefer. Adherence</source><year>2008</year><volume>2</volume><fpage>157</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">19920957</pub-id></element-citation></ref><ref id="B47-cancers-15-01381"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Derry</surname><given-names>H.M.</given-names></name>
<name><surname>Maciejewski</surname><given-names>P.K.</given-names></name>
<name><surname>Epstein</surname><given-names>A.S.</given-names></name>
<name><surname>Shah</surname><given-names>M.A.</given-names></name>
<name><surname>LeBlanc</surname><given-names>T.W.</given-names></name>
<name><surname>Reyna</surname><given-names>V.</given-names></name>
<name><surname>Prigerson</surname><given-names>H.G.</given-names></name>
</person-group><article-title>Associations between Anxiety, Poor Prognosis, and Accurate Understanding of Scan Results among Advanced Cancer Patients</article-title><source>J. Palliat. Med.</source><year>2019</year><volume>22</volume><fpage>961</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1089/jpm.2018.0624</pub-id><pub-id pub-id-type="pmid">30724692</pub-id></element-citation></ref><ref id="B48-cancers-15-01381"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martinez-Lorca</surname><given-names>A.</given-names></name>
</person-group><article-title>Influence of Music in Anxiety Reduction in 18F-FDG PET-CT Studies</article-title><source>Int. J. Radiol. Imaging Technol.</source><year>2022</year><volume>8</volume><fpage>88</fpage><pub-id pub-id-type="doi">10.23937/2572-3235.1510088</pub-id></element-citation></ref><ref id="B49-cancers-15-01381"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sklenarova</surname><given-names>H.</given-names></name>
<name><surname>Kr&#x000fc;mpelmann</surname><given-names>A.</given-names></name>
<name><surname>Haun</surname><given-names>M.W.</given-names></name>
<name><surname>Friederich</surname><given-names>H.-C.</given-names></name>
<name><surname>Huber</surname><given-names>J.</given-names></name>
<name><surname>Thomas</surname><given-names>M.</given-names></name>
<name><surname>Winkler</surname><given-names>E.C.</given-names></name>
<name><surname>Herzog</surname><given-names>W.</given-names></name>
<name><surname>Hartmann</surname><given-names>M.</given-names></name>
</person-group><article-title>When do we need to care about the caregiver? Supportive care needs, anxiety, and depression among informal caregivers of patients with cancer and cancer survivors</article-title><source>Cancer</source><year>2015</year><volume>121</volume><fpage>1513</fpage><lpage>1519</lpage><pub-id pub-id-type="doi">10.1002/cncr.29223</pub-id><pub-id pub-id-type="pmid">25677095</pub-id></element-citation></ref><ref id="B50-cancers-15-01381"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trevino</surname><given-names>K.M.</given-names></name>
<name><surname>Prigerson</surname><given-names>H.G.</given-names></name>
<name><surname>Maciejewski</surname><given-names>P.K.</given-names></name>
</person-group><article-title>Advanced cancer caregiving as a risk for major depressive episodes and generalized anxiety disorder</article-title><source>Psycho-Oncol.</source><year>2018</year><volume>27</volume><fpage>243</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1002/pon.4441</pub-id><pub-id pub-id-type="pmid">28426918</pub-id></element-citation></ref><ref id="B51-cancers-15-01381"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hahne</surname><given-names>J.</given-names></name>
<name><surname>Carpenter</surname><given-names>B.</given-names></name>
<name><surname>Epstein</surname><given-names>A.</given-names></name>
<name><surname>Prigerson</surname><given-names>H.G.</given-names></name>
<name><surname>Derry-Vick</surname><given-names>H.M.</given-names></name>
</person-group><article-title>Communication skills training for oncology clinicians after the 21st Century Cures Act: The need to contextualize patient portal-delivered test results</article-title><source>JCO Oncol. Pract.</source><year>2022</year><fpage>OP-22</fpage><pub-id pub-id-type="doi">10.1200/OP.22.00567</pub-id></element-citation></ref><ref id="B52-cancers-15-01381"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heathcote</surname><given-names>L.C.</given-names></name>
<name><surname>Cunningham</surname><given-names>S.J.</given-names></name>
<name><surname>Webster</surname><given-names>S.N.</given-names></name>
<name><surname>Tanna</surname><given-names>V.</given-names></name>
<name><surname>Mattke</surname><given-names>E.</given-names></name>
<name><surname>Loecher</surname><given-names>N.</given-names></name>
<name><surname>Spunt</surname><given-names>S.L.</given-names></name>
<name><surname>Simon</surname><given-names>P.</given-names></name>
<name><surname>Dahl</surname><given-names>G.</given-names></name>
<name><surname>Walentynowicz</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Smartphone-based Ecological Momentary Assessment to study &#x0201c;scanxiety&#x0201d; among Adolescent and Young Adult survivors of childhood cancer: A feasibility study</article-title><source>Psychooncology</source><year>2022</year><volume>31</volume><fpage>1322</fpage><lpage>1330</lpage><pub-id pub-id-type="doi">10.1002/pon.5935</pub-id><pub-id pub-id-type="pmid">35411626</pub-id></element-citation></ref><ref id="B53-cancers-15-01381"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rankin</surname><given-names>K.</given-names></name>
<name><surname>Walsh</surname><given-names>L.C.</given-names></name>
<name><surname>Sweeny</surname><given-names>K.</given-names></name>
</person-group><article-title>A better distraction: Exploring the benefits of flow during uncertain waiting periods</article-title><source>Emotion</source><year>2019</year><volume>19</volume><fpage>818</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1037/emo0000479</pub-id><pub-id pub-id-type="pmid">30265082</pub-id></element-citation></ref><ref id="B54-cancers-15-01381"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>J.A.</given-names></name>
<name><surname>Zawadzki</surname><given-names>M.J.</given-names></name>
<name><surname>Materia</surname><given-names>F.T.</given-names></name>
<name><surname>White</surname><given-names>A.C.</given-names></name>
<name><surname>Smyth</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Efficacy and acceptability of digital stress management micro-interventions</article-title><source>Procedia Comput. Sci.</source><year>2022</year><volume>206</volume><fpage>45</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.procs.2022.09.084</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="cancers-15-01381-f001"><label>Figure 1</label><caption><p>PRISMA diagram.</p></caption><graphic xlink:href="cancers-15-01381-g001" position="float"/></fig><fig position="float" id="cancers-15-01381-f002"><label>Figure 2</label><caption><p>Dimensions of scanxiety, clustering around scan procedures and scan results.</p></caption><graphic xlink:href="cancers-15-01381-g002" position="float"/></fig><table-wrap position="float" id="cancers-15-01381-t001"><object-id pub-id-type="pii">cancers-15-01381-t001_Table 1</object-id><label>Table 1</label><caption><p>Eligibility criteria for full text screening.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Inclusion</italic>:<break/><list list-type="bullet"><list-item><p>Participants: Adults (ages 18 and older) with current or prior cancer diagnosis</p></list-item><list-item><p>Concept: Undergoing imaging tests for detecting disease progression or recurrence</p></list-item><list-item><p>Context: Completed a measure of psychological symptoms while awaiting scans or scan results or provided retrospective recollection of such symptoms.</p></list-item><list-item><p>Types of studies: Observational studies, case studies, qualitative studies, conference abstracts, and intervention studies (single-arm and randomized controlled trials)</p></list-item></list></td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Exclusion</italic>:<break/><list list-type="bullet"><list-item><p>Study sample composed primarily of children (mean sample age under 18 years), due to likely differences in scan experiences and assessment methods</p></list-item><list-item><p>People undergoing initial diagnostic cancer screening (i.e., no current or prior cancer diagnosis)</p></list-item><list-item><p>Scans or scan result discussions not considered in study design, measurement, or results</p></list-item><list-item><p>Review articles or study protocols</p></list-item><list-item><p>Full text unavailable in English</p></list-item></list></td></tr></tbody></table></table-wrap><table-wrap position="float" id="cancers-15-01381-t002"><object-id pub-id-type="pii">cancers-15-01381-t002_Table 2</object-id><label>Table 2</label><caption><p>Definitions of scanxiety listed in included articles.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x0201c;Ten years ago, Feiler coined the term, &#x02018;scanxiety&#x02019; to describe the emotional distress that patients experience immediately before or after medical imaging [<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>].&#x0201d;</p></list-item><list-item><p>&#x0201c;Scanxiety represents a complex array of negative and stressful emotions linked with cancer scans, and the uncertainties and fears that may accompany them [<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>].&#x0201d;</p></list-item><list-item><p>&#x0201c;Scanxiety&#x0201d; or scan-associated anxiety describes the distress before, during, or after a cancer-related scan and was a term first coined by a patient writing for the Time magazine in 2011. &#x02026; There are no agreed criteria that define scanxiety. Unlike anxiety disorders, which are characterised by excessive fear and anxiety, scanxiety is often considered a normal reaction to a scan. Scanxiety is a transitory emotional state, which is consistent with the concept of state anxiety [<xref rid="B19-cancers-15-01381" ref-type="bibr">19</xref>]. Though scanxiety may not be pathological in the same manner as an anxiety disorder, scanxiety may be a negative experience that impairs quality of life [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>].&#x0201d;</p></list-item><list-item><p>&#x0201c;Distress leading up to, during and after an imaging scan has been termed &#x02018;scanxiety&#x02019; [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>].&#x0201d;</p></list-item><list-item><p>&#x0201c;&#x02018;Scanxiety&#x02019; refers to the often-debilitating anxiety patients with cancer experience in the period surrounding imaging studies for their cancer [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>].&#x0201d;</p></list-item></list>
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="cancers-15-01381-t003"><object-id pub-id-type="pii">cancers-15-01381-t003_Table 3</object-id><label>Table 3</label><caption><p>Summary of included articles.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Sample Characteristics</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Scan Characteristics</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Scanxiety Measures</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Citation</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Type</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Stage</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Status</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scan Type</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scan Purpose</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Assessment Tool</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scan-Specific vs. General Measure</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Design; Assessment Time Points</th></tr></thead><tbody><tr><td colspan="10" align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1">Quantitative Studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abreu et al., 2017 [<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">232</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F-FDG PET/CT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Staging/early post-diagnosis<break/>Detect progression<break/>Detect recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Likert item (anxiety, 10-point)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scan-specific</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Longitudinal:<break/>Immediately pre- and post-scan procedure</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bauml et al., 2016 [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">103</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III, IV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Living with cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Examples given: CT, MRI, PET</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect progression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Impact of Events Scale-6 item version (IES-6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scan-specific</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional:<break/>Waiting room prior to medical oncology appointment (scans discussed for 73% of patients)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bjelic-Radisic et al., 2017 [<xref rid="B42-cancers-15-01381" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">284</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;IV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple aspects of follow-up: Mammography, breast ultrasound, abdominal ultrasound, chest x-ray, bone scintigraphy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer psychosocial assessment screening scale (BC-PASS)Likert items <break/>(distress about follow-up components, 1&#x02013;4)<break/>Likert items (anxiety and stress before follow-up visits; 0&#x02013;10 and 1&#x02013;4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General (BC-PASS)<break/>Scan-specific (Likert items) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional:<break/>Not specified with respect to scan</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cox et al., 2013 [<xref rid="B22-cancers-15-01381" ref-type="bibr">22</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">613; varied by analysis </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple; prior childhood cancers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammogram, ECG (ultrasound or multi-gated acquisition scan), bone density scan (DEXA or CT)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect recurrence <break/>Other: Detect late effects</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three summed items on health fears (future health, cancer recurrence, finding a problem at follow-up visits; 1&#x02013;5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Longitudinal:<break/>Not specified with respect to scan</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Derry et al., 2019 [<xref rid="B47-cancers-15-01381" ref-type="bibr">47</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple; solid tumors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III, IV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Living with cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect progression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single item (anxiety about diagnosis, not at all to completely)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional: <break/>Prior to scan results discussion appointment</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Goense et al., 2018 [<xref rid="B39-cancers-15-01381" ref-type="bibr">39</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Esophageal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Living with cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRI and PET/CT to predict clinical response to neoadjuvant tx</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Staging/early post-diagnosis information</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Likert rating (anxiety, 1&#x02013;5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scan-specific</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional:<break/>Directly following the last of several MRI and PET/CT scans</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Grilo et al., 2017 [<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><sup>18</sup>F-FDG PET/CT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Staging/early post-diagnosis<break/>Detect progression <break/>Detect recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">State Trait Anxiety Inventory (STAI)-state</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Longitudinal:<break/>Before and after scan</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hay et al., 2018 [<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">452</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Living with cancer<break/><break/>Post-treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified; item asked about radiation from medical imaging tests such as x-rays, mammograms, radioactive dye, etc. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single item from HINTS on Medical Imaging Radiation (MIR) worry (not at all to a lot)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scan-specific</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional:<break/>Not specified with respect to scan</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Jeppesen et al., 2018 [<xref rid="B43-cancers-15-01381" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">214</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Endometrial</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ultrasound; other imaging as needed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fear of Cancer Recurrence Inventory (FCRI)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intervention trial: Not specified with respect to scan</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Koinis et al., 2022 [<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">218</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Living with cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect progression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Modified Greek version of Impact of Events Scale (IES)-Revised</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scan-specific</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional: <break/>Within one week after scan</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Krajewski et al., 2017 [<xref rid="B23-cancers-15-01381" ref-type="bibr">23</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bladder</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified; non-muscle- invasive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Living with cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cystoscopy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect progression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hospital Anxiety and Depression Scale (HADS)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Longitudinal:<break/>Directly before procedure and within 7&#x02013;10 days after</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lo Re et al., 2016 [<xref rid="B20-cancers-15-01381" ref-type="bibr">20</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">260 (41% were oncology patients)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRI, breast imaging (mammogram, ultrasound, breast MRI), x-ray, CT, ultrasound</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STAI-state<break/>STAI-trait</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional:<break/>Before scan procedure (presumably in waiting area)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Martinez-Lorca and Martinez-Lorca, 2022 [<xref rid="B48-cancers-15-01381" ref-type="bibr">48</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Living with cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><sup>18</sup>F-FDG-PET-TAC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Early post-diagnosis/staging<break/>Detect progression <break/>Detect recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STAI<break/>Likert scale (subjective anxiety, 0&#x02013;10)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intervention trial: Directly before and after scan</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">McGinty et al., 2014 [<xref rid="B24-cancers-15-01381" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">136</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;IIIA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammogram</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Worry Scale (CWS)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Longitudinal:<break/>Immediately before and one week after mammogram (following negative results)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">McGinty et al., 2016 [<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">161</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;IIIA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammogram</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two visual analog scale items about fear of recurrence<break/><break/>CWS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Longitudinal:<break/>Seven time points; baseline, one month before, one week before, immediately prior to mammogram, and immediately after, one week after, and one month after receiving results</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Morreale et al., 2020 [<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung <break/>Gastrointestinal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Living with cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CT or MRI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect progression/assess treatment response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Distress Thermometer<break/><break/>HADS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Longitudinal:<break/>On imaging day and one week after receiving results</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patel et al., 2016 [<xref rid="B16-cancers-15-01381" ref-type="bibr">16</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">539</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kidney</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Living with cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Axial imaging (CT or MRI), ultrasound</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect progression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-12 QOL Questionnaire Mental Component Score</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Longitudinal:<break/>Not specified with respect to scan</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Porter et al., 2003 [<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55 (34 with breast cancer and 21 without cancer)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammogram</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Daily stress (single item, 0&#x02013;10)<break/><break/>Psychological consequences questionnaire (PCQ)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General (daily stress) <break/>Scan-specific (PCQ)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Longitudinal:<break/>Daily measures for three days about one month before, day of, and day after mammogram</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shelby et al., 2012 [<xref rid="B26-cancers-15-01381" ref-type="bibr">26</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">204</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I-III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammogram</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stanford acute stress reaction questionnaire</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scan-specific</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Longitudinal:<break/>Immediately before mammogram; adherence over next year</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Soriano et al., 2018 [<xref rid="B28-cancers-15-01381" ref-type="bibr">28</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57 couples</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammogram</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Daily measure, six items adapted from Insight and Severity subscales of FCRI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Longitudinal:<break/>Daily measures over three weeks; two weeks before and one week after mammogram</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Soriano et al., 2019 [<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57 couples</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammogram</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Daily measure, six items adapted from Insight and Severity subscales of FCRI<break/><break/>PROMIS Anxiety Short Form</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Longitudinal:<break/>Baseline anxiety; Daily measures over three weeks; two weeks before and one week after mammogram (results typically given same-day)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Westerterp et al., 2008 [<xref rid="B46-cancers-15-01381" ref-type="bibr">46</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">82</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Esophageal </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I-IV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Living with cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CT, PET, cervical ultrasonography, endoscopy, ultrasonography</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Staging/early treatment planning</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Likert item (anxiety; 1&#x02013;5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scan-specific</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional: <break/>two weeks after scan procedures</td></tr><tr><td colspan="10" align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1">Qualitative studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Allen, 2002 [<xref rid="B44-cancers-15-01381" ref-type="bibr">44</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified; non-metastatic </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammogram</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Semi-structured individual interview</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional: <break/>Not specified with respect to scans</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brandzel et al., 2017 [<xref rid="B40-cancers-15-01381" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammogram and breast MRI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Semi-structured interview in focus groups</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scan-specific</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional: Not specified with respect to scans</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bui et al., 2021 [<xref rid="B2-cancers-15-01381" ref-type="bibr">2</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple; <break/>solid tumors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III, IV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Living with cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect progression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Semi-structured individual interview</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scan-specific</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional: Within four months after scan</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lai-Kwon et al., 2021 [<xref rid="B34-cancers-15-01381" ref-type="bibr">34</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Living with cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CT; PET</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect progression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Semi-structured individual interview</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scan-specific</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional: <break/>Within three months after scans</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mannion et al., 2022 [<xref rid="B31-cancers-15-01381" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified; included those with Stage IV cancer (80%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Living with cancer<break/><break/>Post-treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect progression<break/>Detect recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Semi-structured individual interview</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scan-specific</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional: <break/>Not specified with respect to scans</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pascal and Endacott 2010 [<xref rid="B33-cancers-15-01381" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Variety including mammograms and other scans</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In-depth individual interview</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Longitudinal: <break/>Two interviews over six months, timing not specified with respect to scans</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sterba et al., 2015 [<xref rid="B36-cancers-15-01381" ref-type="bibr">36</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colorectal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I-III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified; regular follow up including CT and colonoscopy </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Semi-structured interview in focus groups</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional: Not specified with respect to scans</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thompson, H.S. et al., 2006 [<xref rid="B45-cancers-15-01381" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Variable as part of follow-up care; e.g., mammogram, x-ray, sonogram, CT, PET </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Semi-structured individual interview</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional: Not specified with respect to scans</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wernli et al., 2017 [<xref rid="B32-cancers-15-01381" ref-type="bibr">32</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammogram and breast MRI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Semi-structured interview in focus groups</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scan-specific</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional: Not specified with respect to scans</td></tr><tr><td colspan="10" align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1">Mixed methods studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baun et al., 2020 [<xref rid="B37-cancers-15-01381" ref-type="bibr">37</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Living with cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CT or combined PET/CT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect progression/monitor treatment response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quantitative assessment focused on patients&#x02019; use of electronic records for test results (not anxiety) followed by semi-structured individual interviews</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sequential: <break/>Not specified with respect to scans </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bellhouse et al., 2020 [<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I-III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Living with cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Radiotherapy planning CT and two MRI scans approximately two weeks apart</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other: Radiotherapy planning</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STAI-state<break/><break/>Claustrophobia Questionnaire (CLQ)<break/><break/>MRI anxiety questionnaire (MRI-AQ)<break/><break/>CT anxiety questionnaire (CT-AQ)<break/><break/>Semi-structured individual interview after last scan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General (STAI-S, CLQ)<break/><break/>Scan-specific (MRI-AQ, CT-AQ, interview guide)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Longitudinal, concurrent:<break/>Baseline and after each MRI scan</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bui et al., 2022 [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">222</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple; solid tumors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III, IV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Living with cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect progression<break/><break/>Investigative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single item (experience scanxiety; yes/no)<break/><break/>Modified Distress Thermometer<break/><break/>Open-ended text response<break/><break/>Other measures examined as correlates: six-item STAI, HADS, FOP-Q-SF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scan-specific (single item, modified Distress Thermometer, open text)<break/><break/>General (FOP, STAI, HADS)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Concurrent: <break/>Within four months after scan/scan results</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Koo et al., 2017 [<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bladder</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0; non-muscle-invasive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Living with cancer<break/><break/>Post-treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cystoscopy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect progression<break/><break/>Detect recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Psychological consequences of screening questionnaire (PCQ)<break/><break/>Customer satisfaction survey (CSS) with items on worry and discomfort from procedure<break/><break/>Semi-structured interview in focus groups</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scan-specific </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sequential:<break/>After cystoscopy procedure</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thompson, C.A. et al., 2010 [<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hodgkin&#x02019;s lymphoma<break/><break/>Aggressive non-Hodgkin&#x02019;s lymphoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detect recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STAI-trait <break/><break/>Semi-structured individual interviews</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General (STAI) <break/><break/>Scan-specific (interview guide)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Concurrent: <break/>Not specified with respect to scan (mean time since last scan = 14.8 months, SD 25.3) </td></tr></tbody></table></table-wrap><table-wrap position="float" id="cancers-15-01381-t004"><object-id pub-id-type="pii">cancers-15-01381-t004_Table 4</object-id><label>Table 4</label><caption><p>Quantitative measures of scanxiety used in included articles, according to scan-specific vs. general assessments.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1">Scan-Specific Measures<break/>(Worded with Respect to Scans)</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1">General Measures<break/>(Worded without Reference to Scans)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Measure</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n, Articles</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Measure</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n, Articles</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Impact of Events Scale (IES; revised or short form)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 [<xref rid="B3-cancers-15-01381" ref-type="bibr">3</xref>,<xref rid="B17-cancers-15-01381" ref-type="bibr">17</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">State-Trait Anxiety Inventory (STAI)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 [<xref rid="B13-cancers-15-01381" ref-type="bibr">13</xref>,<xref rid="B18-cancers-15-01381" ref-type="bibr">18</xref>,<xref rid="B20-cancers-15-01381" ref-type="bibr">20</xref>,<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>,<xref rid="B48-cancers-15-01381" ref-type="bibr">48</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Modified Distress Thermometer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fear of Cancer Recurrence Inventory (FCRI)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 [<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>,<xref rid="B28-cancers-15-01381" ref-type="bibr">28</xref>,<xref rid="B43-cancers-15-01381" ref-type="bibr">43</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Psychological Consequences of Screening Questionnaire (PCQ) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 [<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>,<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hospital Anxiety and Depression Scale (HADS)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 [<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>,<xref rid="B23-cancers-15-01381" ref-type="bibr">23</xref>,<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRI Anxiety Questionnaire </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Worry Scale (CWS)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 [<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>,<xref rid="B24-cancers-15-01381" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CT Anxiety Questionnaire</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Claustrophobia Questionnaire </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B41-cancers-15-01381" ref-type="bibr">41</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medical Imaging Radiation Worry item from the HINTS survey </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B38-cancers-15-01381" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast Cancer Psychosocial Assessment </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B42-cancers-15-01381" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stanford Acute Stress Reaction Questionnaire </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B26-cancers-15-01381" ref-type="bibr">26</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Health Fears items </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B22-cancers-15-01381" ref-type="bibr">22</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Customer Satisfaction Survey (worry and discomfort items)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B30-cancers-15-01381" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-12 Quality of Life Mental Component Score</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B16-cancers-15-01381" ref-type="bibr">16</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study-specific item (anxiety during procedure, 10-point Likert)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B21-cancers-15-01381" ref-type="bibr">21</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Visual analog scale (VAS) items on fear of recurrence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B14-cancers-15-01381" ref-type="bibr">14</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study-specific item (distress about components of follow-up, 4-point Likert)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B42-cancers-15-01381" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fear of Progression Questionnaire </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study-specific item (anxiety about diagnosis, not at all to completely)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B47-cancers-15-01381" ref-type="bibr">47</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PROMIS Global Anxiety </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B27-cancers-15-01381" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study-specific item (anxiety during procedure, 5-point Likert)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B39-cancers-15-01381" ref-type="bibr">39</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study-specific item, daily stress (0&#x02013;10 Likert)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B25-cancers-15-01381" ref-type="bibr">25</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study-specific item (anxiety about scan modalities, 5-point Likert)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B46-cancers-15-01381" ref-type="bibr">46</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study-specific item, subjective anxiety (0&#x02013;10 Likert)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B48-cancers-15-01381" ref-type="bibr">48</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study-specific item (whether experienced scanxiety; yes/no)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B29-cancers-15-01381" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Distress Thermometer (general)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B15-cancers-15-01381" ref-type="bibr">15</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Note: Measures were used to assess psychological symptoms around the time of scans or with consideration of scans in the study design. Scan-specific assessments were specifically worded in reference to a scan; general measures did not include a specific focus.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="cancers-15-01381-t005"><object-id pub-id-type="pii">cancers-15-01381-t005_Table 5</object-id><label>Table 5</label><caption><p>Recommended areas for future scanxiety research.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1">
<bold>
<italic toggle="yes">Research Topics: Expanding Research to Areas Needing Additional Attention</italic>
</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Suggested Areas</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Example Research Questions</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Investigate care partners&#x02019; scanxiety levels and supportive care needs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>What are the scanxiety characteristics, levels, and support needs among care partners/family members?</p></list-item><list-item><p>How do care partners&#x02019; scanxiety compare to and influence that of the cancer survivor?</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Determine whether people with cancer experience similar anxiety and uncertainty while awaiting different types of tests </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>How does anxiety fluctuate in the time period around cancer-monitoring blood tests and results delivery?</p></list-item><list-item><p>What are the components or dimensions of anxiety around these procedures?</p></list-item><list-item><p>What are the correlates and effects of anxiety around other tests?</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Explore how newer modes of scan results delivery (e.g., via electronic results release; via video or other remote clinical interactions) affect scanxiety </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Which patients experience decreased anxiety when receiving faster, automated test results (e.g., in patient portals)&#x02014;and which patients experience elevated anxiety?</p></list-item><list-item><p>What support strategies may patients need in order to engage with and benefit from this format of results delivery?</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Expand scanxiety research to under-investigated populations, time periods, and scan types</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>What are the scanxiety experiences and coping strategies of those with hematological malignancies?</p></list-item><list-item><p>How does anxiety fluctuate between the scan procedure and the scan results? What factors may exacerbate or buffer against increases?</p></list-item><list-item><p>How do patients cope with anxiety in the context of investigative scans prompted by new or worsening symptoms?</p></list-item><list-item><p>What are the longitudinal patterns of scanxiety that occur over time with repeated scans?</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Expand work on the effects of scanxiety and moderators of these effects</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>For whom and how does scanxiety affect one&#x02019;s likelihood of adhering to follow-up care?</p></list-item><list-item><p>How does scanxiety impact physical symptoms, communication in appointments, and other outcomes?</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Determine intervention targets and test whether interventions are effective </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Are brief interventions (e.g., just-in-time micro-interventions) acceptable, feasible, and efficacious for reducing anxiety at the time of scan procedures?</p></list-item><list-item><p>Which coping strategies are most effective for managing uncertainty about what results may show?</p></list-item><list-item><p>When is the optimal time to introduce a behavioral intervention with respect to scans?</p></list-item></list>
</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1">
<bold>
<italic toggle="yes">Research Methods: Strengthening how Scanxiety Studies Are Conducted</italic>
</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Suggested Approaches</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Example Research Questions/Directions</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Harmonize measures and examine psychometrics</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>How does scanxiety relate to close constructs such as fear of recurrence or progression, anticipatory anxiety, and state anxiety?</p></list-item><list-item><p>Is it sufficient to use existing state anxiety measures to index scanxiety? Or are there advantages to developing specific measures that reflect multiple elements or specific components of scanxiety?</p></list-item><list-item><p>Examine psychometrics of scanxiety measures</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improve description of follow-up care procedures</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Strengthen descriptions of what typical follow-up procedures entail (e.g., exams, tests)</p></list-item><list-item><p>In studies of general anxiety, include questions about whether an upcoming scan or scan discussion is occurring</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detail time periods to include information on procedures and scan results delivery phases </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Describe the length of time between assessment time points with respect to pre-scan, post-scan, and results delivery time points.</p></list-item><list-item><p>Report whether, when, and how results were delivered, and what they showed.</p></list-item><list-item><p>How do waiting periods and results delivery methods influence scanxiety?</p></list-item><list-item><p>How can clinicians or clinics structure the scan experience to help mitigate anxiety?</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Explore innovative measurement strategies</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Are daily diary and/or ecological momentary assessment approaches acceptable and feasible around the time of scans for older adults, those with advanced disease, and those on active treatment?</p></list-item><list-item><p>Do these approaches reveal fluctuations and individual differences not evident from one-time assessments?</p></list-item></list>
</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1">
<bold>
<italic toggle="yes">Intervention Approaches: Developing and Testing Ways to Manage Scanxiety</italic>
</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Promising Approaches</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Example Research Directions/Intervention Targets</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Screening to identify those experiencing or at higher risk for scanxiety</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Use scan-specific measures to identify those with scanxiety</p></list-item><list-item><p>Prioritize at-risk individuals for interventions</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tailoring strategies to stressful time periods</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Design interventions that address procedure-related and results-related components of scanxiety</p></list-item><list-item><p>Optimize strategies for each time period (e.g., pre-scan; awaiting results)</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Behavioral / self-management strategies</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Promote self-efficacy for coping with progression/recurrence</p></list-item><list-item><p>Bolster overall stress management skills (e.g., relaxation, pleasant activities)</p></list-item><list-item><p>Facilitate just-in-time strategies for distinct periods (e.g., during or directly before scans)</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinic or system strategies</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Reduce scan-to-results waiting time</p></list-item><list-item><p>Provide education/structure that promotes knowing what to expect for the procedure</p></list-item><list-item><p>Engage in shared decision-making about scans and results delivery</p></list-item></list>
</td></tr></tbody></table></table-wrap></floats-group></article>
